1
|
Ferriero M, Prata F, Anceschi U, Astore S, Bove AM, Brassetti A, Calabrò F, Chiellino S, De Nunzio C, Facchini G, Franzese E, Izzo M, Mastroianni R, Misuraca L, Naspro R, Papalia R, Pappalardo A, Tema G, Tuderti G, Turchi B, Tubaro A, Simone G. Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort. Cancers (Basel) 2023; 15:4809. [PMID: 37835503 PMCID: PMC10571997 DOI: 10.3390/cancers15194809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 09/10/2023] [Accepted: 09/25/2023] [Indexed: 10/15/2023] Open
Abstract
Registrative trials recommended the use of upfront chemotherapy in high-volume metastatic prostate cancer. We reported survival outcomes of patients with high-volume mCRPC treated with ARTA in a chemo-naïve setting compared to patients treated with chemotherapy as first-line from a longitudinal real-life multicenter series. We retrospectively collected data on mCRPC patients treated at six centers. The dataset was queried for high-volume disease (defined as more than 6 bone lesions or bulky nodes ≥ 5 cm). We compared the main clinical features of chemo-naïve versus chemo-treated patients. The Mann-Whitney U test and Chi-squared test were used to compare continuous and categorial variables, respectively. The Kaplan-Meier method was used to compare differences in terms of progression-free survival (PFS), cancer specific survival (CSS) and overall survival (OS) in an upfront ARTA or chemo-treated setting. Survival probabilities were computed at 12, 24, 48, and 60 months. Out of 216 patients, 88 cases with high-volume disease were selected. Sixty-nine patients (78.4%) received upfront ARTA, while 19 patients received chemotherapy as the first-line treatment option. Forty-eight patients received Abiraterone (AA), 21 patients received Enzalutamide (EZ) as the first-line treatment. The ARTA population was older (p = 0.007) and less likely to receive further lines of treatment (p = 0.001) than the chemo-treated cohort. The five-year PFS, CSS and OS were 60%, 73.3%, and 72.9%, respectively. Overall, 28 patients (31.8%) shifted after their first-line therapy to a second-line therapy: EZ was prescribed in 17 cases, AA in seven cases and radiometabolic therapy in four patients. Sixteen cases (18.2%) developed significant progression and were treated with chemotherapy. At Kaplan-Meyer analysis PFS, CSS and OS were comparable for upfront ARTA vs chemo-treated patients (log rank p = 0.10, p = 0.64 and p = 0.36, respectively). We reported comparable survival probabilities in a real-life series of high-volume mCRPC patients who either received upfront ARTA or chemotherapy. Patients primarily treated with chemotherapy were younger and more likely to receive further treatment lines than the upfront ARTA cohort. Our data support the use of novel antiandrogens as first line treatment regardless tumor burden, delaying the beginning of a more toxic chemotherapy in case of significant disease progression.
Collapse
Affiliation(s)
- Mariaconsiglia Ferriero
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
| | - Francesco Prata
- Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy; (F.P.); (R.P.)
| | - Umberto Anceschi
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
| | - Serena Astore
- Department of Medical Oncology, San Camillo-Forlanini Hospital, 00149 Rome, Italy;
| | - Alfredo Maria Bove
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
| | - Aldo Brassetti
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
| | - Fabio Calabrò
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
- Department of Medical Oncology, San Camillo-Forlanini Hospital, 00149 Rome, Italy;
| | - Silvia Chiellino
- Department of Oncology, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy; (S.C.)
| | - Cosimo De Nunzio
- Department of Urology, Faculty of Health Sciences, “Sapienza” University, Ospedale Sant’Andrea, 00185 Rome, Italy; (C.D.N.); (B.T.); (A.T.)
| | - Gaetano Facchini
- Medical Oncology Complex Unit, “Santa Maria della Grazie” Hospital, ASL Napoli 2 Nord, 80078 Pozzuoli, Italy
| | - Elisena Franzese
- Medical Oncology Complex Unit, “Santa Maria della Grazie” Hospital, ASL Napoli 2 Nord, 80078 Pozzuoli, Italy
| | - Michela Izzo
- Medical Oncology Complex Unit, “Santa Maria della Grazie” Hospital, ASL Napoli 2 Nord, 80078 Pozzuoli, Italy
| | - Riccardo Mastroianni
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
| | - Leonardo Misuraca
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
| | - Richard Naspro
- Department of Urology, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy; (R.N.)
| | - Rocco Papalia
- Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy; (F.P.); (R.P.)
| | - Annalisa Pappalardo
- Medical Oncology Complex Unit, “Santa Maria della Grazie” Hospital, ASL Napoli 2 Nord, 80078 Pozzuoli, Italy
| | - Giorgia Tema
- Department of Urology, Faculty of Health Sciences, “Sapienza” University, Ospedale Sant’Andrea, 00185 Rome, Italy; (C.D.N.); (B.T.); (A.T.)
| | - Gabriele Tuderti
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
| | - Beatrice Turchi
- Department of Urology, Faculty of Health Sciences, “Sapienza” University, Ospedale Sant’Andrea, 00185 Rome, Italy; (C.D.N.); (B.T.); (A.T.)
| | - Andrea Tubaro
- Department of Urology, Faculty of Health Sciences, “Sapienza” University, Ospedale Sant’Andrea, 00185 Rome, Italy; (C.D.N.); (B.T.); (A.T.)
| | - Giuseppe Simone
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00144 Rome, Italy; (U.A.); (A.M.B.); (A.B.); (R.M.); (L.M.); (G.T.); (G.S.)
| |
Collapse
|
2
|
Giunta EF, Arrichiello G, Pappalardo A, Federico P, Petrillo A. Transversal Perspectives of Integrative Oncology Care in Gastric and Lobular Breast Cancer. Cancer Treat Res 2023; 188:89-104. [PMID: 38175343 DOI: 10.1007/978-3-031-33602-7_4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
The occurrence of gastric cancer has been associated with an increased risk of lobular breast tumors in a subset of patients harboring selected germline mutations. Among all, the germline alteration of the gene coding for E-Cadherin (CDH1) was associated with an increased risk of gastric cancer diffuse-histotype and lobular breast cancer. However, the risk assessment of breast neoplasms and the role of multiple prophylactic procedures in these patients has never been systematically addressed. In addition, the performance of the common screening procedures for lobular breast cancer like mammography is suboptimal. Therefore, recalling the need for a better articulation of the patient-centered strategies of surveillance for individuals with germline CDH1 and other similar alterations, to offer comprehensive approaches for prevention, early diagnosis, and treatment. Accordingly, this chapter aims to discuss the value and the role of integrated oncological care in the era of oncology sub-specializations. Additionally, it sheds light on how the harmonization across the health providers can enhance patient care in this setting.
Collapse
Affiliation(s)
- Emilio Francesco Giunta
- Department of Precision Medicine, School of Medicine, University of Study of Campania, 80131, Naples, Italy
| | - Gianluca Arrichiello
- Department of Precision Medicine, School of Medicine, University of Study of Campania, 80131, Naples, Italy
| | | | - Piera Federico
- Medical Oncology Unit, Ospedale del Mare, Via E. Russo, 80147, Naples, Italy
| | - Angelica Petrillo
- Medical Oncology Unit, Ospedale del Mare, Via E. Russo, 80147, Naples, Italy.
| |
Collapse
|
3
|
Sorrells L, Pappalardo A, Alvarez-Cespedes D, Jeon E, Abaci H. 767 A biopsy-sized 3D model of skin vascular plexus and appendages enables monitoring T cell trafficking. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Jeon E, Pappalardo A, Sorrells L, Abaci H. 707 Guiding skin organoid generation via extracellular matrix cues and spatially controlled morphogen gradients. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
5
|
Pappalardo A, Vasilikos P, Nathaniel M, Guo Z, Abaci H, Christiano A. 602 An in vitro psoriasis model for high throughput screening. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
6
|
Pappalardo A, Alvarez-Cespedes D, Fang S, Herschman A, Jeon E, Myers K, Kysar J, Abaci H. 769 Wearable human skin constructs with region-specific properties. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
7
|
Nevola R, Rosato V, Conturso V, Perillo P, Le Pera T, Del Vecchio F, Mastrocinque D, Pappalardo A, Imbriani S, Delle Femine A, Piacevole A, Claar E. Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. Biology 2022; 11:biology11060805. [PMID: 35741326 PMCID: PMC9219847 DOI: 10.3390/biology11060805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 05/21/2022] [Accepted: 05/21/2022] [Indexed: 11/25/2022]
Abstract
Simple Summary The global fight against the hepatitis C virus (HCV) involves the processes of micro-elimination of populations at risk. People who use drugs (PWUDs) represent a viral reservoir, due to the historical challenge in treating this population. In particular, the difficulties in the linkage to care of these patients, as well as low adherence to therapies and follow-up and the risk of re-infection make PWUDs a “difficult-to-treat” population. In view of this, the testing of effective management and treatment models for chronic HCV infection in PWUDs is crucial for promoting its elimination. Telemedicine could be a successful solution in the integration and decentralization of care services. Abstract People who use drugs (PWUDs) are a crucial population in the global fight against viral hepatitis. The difficulties in linkage to care, the low adherence to therapy, the frequent loss to follow-up and the high risk of re-infection make the eradication process of the hepatitis C virus (HCV) really hard in this viral reservoir. Several management and treatment models have been tested with the aim of optimizing the HCV care cascade in PWUDs. Models of decentralization of the care process and integration of services seem to provide the highest success rates. Giving this, telemedicine could favor the decentralization of diagnostic-therapeutic management, key for the implementation of linkage to care, reduction of waiting times, optimization of adherence and results and reduction of the costs. The purpose of this literature review is to examine the role and possible impact of telemedicine in optimizing the HCV care cascade, comparing the different care models that have shown to improve the linkage to care and therapeutic adherence in this special population.
Collapse
Affiliation(s)
- Riccardo Nevola
- Hepatology Unit, Ospedale Evangelico Betania, 80147 Naples, Italy; (V.R.); (P.P.); (D.M.); (A.P.); (E.C.)
- Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy; (S.I.); (A.D.F.); (A.P.)
- Correspondence: ; Tel.: +39-081-566-4173
| | - Valerio Rosato
- Hepatology Unit, Ospedale Evangelico Betania, 80147 Naples, Italy; (V.R.); (P.P.); (D.M.); (A.P.); (E.C.)
| | - Vincenza Conturso
- Service for Addiction, DS32, ASL Napoli 1, 80147 Naples, Italy; (V.C.); (T.L.P.); (F.D.V.)
| | - Pasquale Perillo
- Hepatology Unit, Ospedale Evangelico Betania, 80147 Naples, Italy; (V.R.); (P.P.); (D.M.); (A.P.); (E.C.)
| | - Teresa Le Pera
- Service for Addiction, DS32, ASL Napoli 1, 80147 Naples, Italy; (V.C.); (T.L.P.); (F.D.V.)
| | - Ferdinando Del Vecchio
- Service for Addiction, DS32, ASL Napoli 1, 80147 Naples, Italy; (V.C.); (T.L.P.); (F.D.V.)
| | - Davide Mastrocinque
- Hepatology Unit, Ospedale Evangelico Betania, 80147 Naples, Italy; (V.R.); (P.P.); (D.M.); (A.P.); (E.C.)
| | - Annalisa Pappalardo
- Hepatology Unit, Ospedale Evangelico Betania, 80147 Naples, Italy; (V.R.); (P.P.); (D.M.); (A.P.); (E.C.)
| | - Simona Imbriani
- Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy; (S.I.); (A.D.F.); (A.P.)
| | - Augusto Delle Femine
- Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy; (S.I.); (A.D.F.); (A.P.)
| | - Alessia Piacevole
- Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy; (S.I.); (A.D.F.); (A.P.)
| | - Ernesto Claar
- Hepatology Unit, Ospedale Evangelico Betania, 80147 Naples, Italy; (V.R.); (P.P.); (D.M.); (A.P.); (E.C.)
| |
Collapse
|
8
|
Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, De Vita F, Petrillo A. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Front Oncol 2021; 11:695627. [PMID: 34485130 PMCID: PMC8415474 DOI: 10.3389/fonc.2021.695627] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 06/16/2021] [Indexed: 12/19/2022] Open
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease even in the early stages, despite progresses in surgical and pharmacological treatment in recent years. High potential for metastases is the main cause of therapeutic failure in localized disease, highlighting the current limited knowledge of underlying pathological processes. However, nowadays research is focusing on the search for personalized approaches also in the adjuvant setting for PDAC, by implementing the use of biomarkers and investigating new therapeutic targets. In this context, the aim of this narrative review is to summarize the current treatment scenario and new potential therapeutic approaches in early stage PDAC, from both a preclinical and clinical point of view. Additionally, the review examines the role of target therapies in localized PDAC and the influence of neoadjuvant treatments on survival outcomes.
Collapse
Affiliation(s)
- Annalisa Pappalardo
- Medical Oncology Unit, Ospedale del Mare, Naples, Italy
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania “L. Vanvitelli”, Naples, Italy
| | - Emilio Francesco Giunta
- Medical Oncology Unit, Ospedale del Mare, Naples, Italy
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania “L. Vanvitelli”, Naples, Italy
| | - Giuseppe Tirino
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania “L. Vanvitelli”, Naples, Italy
| | - Luca Pompella
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania “L. Vanvitelli”, Naples, Italy
| | | | - Bruno Daniele
- Medical Oncology Unit, Ospedale del Mare, Naples, Italy
| | - Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania “L. Vanvitelli”, Naples, Italy
| | - Angelica Petrillo
- Medical Oncology Unit, Ospedale del Mare, Naples, Italy
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania “L. Vanvitelli”, Naples, Italy
| |
Collapse
|
9
|
Pappalardo A, Rami A, Guo Z, Abaci H, Christiano A. 595 Recapitulating atopic dermatitis in vitro with a multi-organ 3D model. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, Fabbrocini A, Petrillo A, Daniele B. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel) 2021; 14:233. [PMID: 33800217 PMCID: PMC8001824 DOI: 10.3390/ph14030233] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 02/27/2021] [Accepted: 03/01/2021] [Indexed: 02/08/2023] Open
Abstract
Hepatocellular carcinoma (HCC) is the primary tumour of the liver with the greatest incidence, particularly in the elderly. Additionally, improvements in the treatments for chronic liver diseases have increased the number of elderly patients who might be affected by HCC. Little evidence exists regarding HCC in old patients, and the elderly are still underrepresented and undertreated in clinical trials. In fact, this population represents a complex subgroup of patients who are hard to manage, especially due to the presence of multiple comorbidities. Therefore, the choice of treatment is mainly decided by the physician in the clinical practice, who often tend not to treat elderly patients in order to avoid the possibility of adverse events, which may alter their unstable equilibrium. In this context, the clarification of the optimal treatment strategy for elderly patients affected by HCC has become an urgent necessity. The aim of this review is to provide an overview of the available data regarding the treatment of HCC in elderly patients, starting from the definition of "elderly" and the geriatric assessment and scales. We explain the possible treatment choices according to the Barcelona Clinic Liver Cancer (BCLC) scale and their feasibility in the elderly population.
Collapse
Affiliation(s)
- Piera Federico
- Medical Oncology Unit, Ospedale del Mare, 80147 Napoli, Italy; (E.F.G.); (A.P.); (L.A.); (A.F.); (A.P.); (B.D.)
| | - Emilio Francesco Giunta
- Medical Oncology Unit, Ospedale del Mare, 80147 Napoli, Italy; (E.F.G.); (A.P.); (L.A.); (A.F.); (A.P.); (B.D.)
- Department of Precision Medicine, School of Medicine, University of Study of Campania “L. Vanvitelli”, 80131 Napoli, Italy
| | - Annalisa Pappalardo
- Medical Oncology Unit, Ospedale del Mare, 80147 Napoli, Italy; (E.F.G.); (A.P.); (L.A.); (A.F.); (A.P.); (B.D.)
- Department of Precision Medicine, School of Medicine, University of Study of Campania “L. Vanvitelli”, 80131 Napoli, Italy
| | - Andrea Tufo
- Surgical Unit, Ospedale del Mare, 80147 Napoli, Italy; (A.T.); (G.M.)
| | - Gianpaolo Marte
- Surgical Unit, Ospedale del Mare, 80147 Napoli, Italy; (A.T.); (G.M.)
| | - Laura Attademo
- Medical Oncology Unit, Ospedale del Mare, 80147 Napoli, Italy; (E.F.G.); (A.P.); (L.A.); (A.F.); (A.P.); (B.D.)
| | - Antonietta Fabbrocini
- Medical Oncology Unit, Ospedale del Mare, 80147 Napoli, Italy; (E.F.G.); (A.P.); (L.A.); (A.F.); (A.P.); (B.D.)
| | - Angelica Petrillo
- Medical Oncology Unit, Ospedale del Mare, 80147 Napoli, Italy; (E.F.G.); (A.P.); (L.A.); (A.F.); (A.P.); (B.D.)
- Department of Precision Medicine, School of Medicine, University of Study of Campania “L. Vanvitelli”, 80131 Napoli, Italy
| | - Bruno Daniele
- Medical Oncology Unit, Ospedale del Mare, 80147 Napoli, Italy; (E.F.G.); (A.P.); (L.A.); (A.F.); (A.P.); (B.D.)
| |
Collapse
|
11
|
Pappalardo A, Warren C, Herbert L, Robinson A, Lombard L, Ramos A, Sharma H, Tobin M, Assa'ad A, Gupta R. P308 CHARACTERIZING FOOD ALLERGY SELF-EFFICACY AMONG PARENTS/CAREGIVERS OF BLACK AND WHITE CHILDREN WITH FOOD ALLERGY. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Solaro C, Di Giovanni R, Grange E, Mueller M, Messmer Uccelli M, Bertoni R, Brichetto G, Tacchino A, Patti F, Pappalardo A, Prosperini L, Castelli L, Rosato R, Cattaneo D, Marengo D. Box and block test, hand grip strength and nine-hole peg test: correlations between three upper limb objective measures in multiple sclerosis. Eur J Neurol 2020; 27:2523-2530. [PMID: 32619066 DOI: 10.1111/ene.14427] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 06/18/2020] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND PURPOSE Limited data are available in the literature for upper limb impairment in multiple sclerosis (MS). This study aimed to report the distribution of values of hand grip strength (HGS), of the box and block test (BBT) and of the nine-hole peg test (9HPT) correlated with demographic and clinical data in subjects with MS. METHODS This study involved five Italian neurological centres. The inclusion criteria were age ≥ 18, MS diagnosis, stable disease phase, right-hand dominance. All subjects underwent HGS, BBT and 9-HPT evaluation. RESULTS In all, 202 subjects with MS were enrolled: 137 females; mean age 48.4 years; mean Expanded Disability Status Scale (EDSS) 4.17; mean disease duration 14.12 years; disease course 129 relapsing-remitting, 21 primary progressive and 52 secondary progressive MS subjects; mean right HGS 25.3 kg, left 23.2 kg; mean right BBT 45.7 blocks, left 44.9 blocks; mean right 9-HPT 30.7 s, left 33.4 s. All results were statistically significantly different compared to healthy controls. HGS, BBT and 9-HPT were associated with age, EDSS and disease duration, whilst disease course correlated with BBT and 9-HPT. The BBT and 9-HPT scores significantly differed according to level of disability (EDSS ≤3.0, 3.5-5.5, ≥6.0). CONCLUSION Hand grip strength and BBT value distribution in a large MS population is reported. Correlations between HGS, BBT and 9-HPT were generally low.
Collapse
Affiliation(s)
- C Solaro
- Department of Rehabilitation, CRRF 'Mons. Luigi Novarese', Moncrivello, Italy
| | - R Di Giovanni
- Department of Rehabilitation, CRRF 'Mons. Luigi Novarese', Moncrivello, Italy
| | - E Grange
- Department of Rehabilitation, CRRF 'Mons. Luigi Novarese', Moncrivello, Italy
| | - M Mueller
- Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genova, Italy
| | - M Messmer Uccelli
- Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genova, Italy
| | - R Bertoni
- IRCCS Fondazione Don Carlo Gnocchi, Milano, Italy
| | - G Brichetto
- Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genova, Italy
| | - A Tacchino
- Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genova, Italy
| | - F Patti
- MS Center Institute of Neurological Sciences - University of Catania, Catania, Italy
| | - A Pappalardo
- MS Center Institute of Neurological Sciences - University of Catania, Catania, Italy
| | - L Prosperini
- Department of Neurosciences, S. Camillo-Forlanini Hospital, Roma, Italy
| | - L Castelli
- Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC neuroriabilitazione ad Alta Intensità, Roma, Italy
| | - R Rosato
- Department of Psychology, University of Turin, Torino, Italy
| | - D Cattaneo
- IRCCS Fondazione Don Carlo Gnocchi, Milano, Italy
| | - D Marengo
- Department of Psychology, University of Turin, Torino, Italy
| |
Collapse
|
13
|
Söderström PA, Capponi L, Açıksöz E, Otsuka T, Tsoneva N, Tsunoda Y, Balabanski DL, Pietralla N, Guardo GL, Lattuada D, Lenske H, Matei C, Nichita D, Pappalardo A, Petruse T. Electromagnetic character of the competitive γγ/γ-decay from 137mBa. Nat Commun 2020; 11:3242. [PMID: 32591502 PMCID: PMC7320027 DOI: 10.1038/s41467-020-16787-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2019] [Accepted: 05/20/2020] [Indexed: 11/09/2022] Open
Abstract
Second-order processes in physics is a research topic focusing attention from several fields worldwide including, for example, non-linear quantum electrodynamics with high-power lasers, neutrinoless double-β decay, and stimulated atomic two-photon transitions. For the electromagnetic nuclear interaction, the observation of the competitive double-γ decay from 137mBa has opened up the nuclear structure field for detailed investigation of second-order processes through the manifestation of off-diagonal nuclear polarisability. Here, we confirm this observation with an 8.7σ significance, and an improved value on the double-photon versus single-photon branching ratio as 2.62 × 10-6(30). Our results, however, contradict the conclusions from the original experiment, where the decay was interpreted to be dominated by a quadrupole-quadrupole component. Here, we find a substantial enhancement in the energy distribution consistent with a dominating octupole-dipole character and a rather small quadrupole-quadrupole component in the decay, hindered due to an evolution of the internal nuclear structure. The implied strongly hindered double-photon branching in 137mBa opens up the possibility of the double-photon branching as a feasible tool for nuclear-structure studies on off-diagonal polarisability in nuclei where this hindrance is not present.
Collapse
Affiliation(s)
- P-A Söderström
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania.
| | - L Capponi
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania
| | - E Açıksöz
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania
| | - T Otsuka
- Center for Nuclear Study, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.,Department of Physics, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.,RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan
| | - N Tsoneva
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania
| | - Y Tsunoda
- Center for Nuclear Study, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - D L Balabanski
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania
| | - N Pietralla
- Institut für Kernphysik, Technische Universität Darmstadt, 64289, Darmstadt, Germany
| | - G L Guardo
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania.,Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali del Sud, 95125, Catania, Italy
| | - D Lattuada
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania.,Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali del Sud, 95125, Catania, Italy.,Universitá degli Studi di Enna KORE, Viale delle Olimpiadi, 94100, Enna, Italy
| | - H Lenske
- Institut für Theoretische Physik, Universität Gießen, 35392, Gießen, Germany
| | - C Matei
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania
| | - D Nichita
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania.,Politehnica University of Bucharest, Splaiul Independentei 313, 060042, Bucharest, Romania
| | - A Pappalardo
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania
| | - T Petruse
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP)/Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Str. Reactorului 30, 077125, Bucharest-Măgurele, Romania.,Politehnica University of Bucharest, Splaiul Independentei 313, 060042, Bucharest, Romania
| |
Collapse
|
14
|
Pappalardo A, Wojciechowski E, Odriozola I, Douchet I, Merillon N, Boizard-Moracchini A, Duffau P, Lazaro E, Doucey MA, Mbow L, Richez C, Blanco P. THU0035 OX40L EXPRESSING NEUTROPHILS INDUCE CD4 T FOLLICULAR AND PERIPHERAL HELPER CELL DIFFERENTIATION IN SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Neutrophils have been described as potent antigen-presenting cells able to activate T cells by MHC/TCR interaction and costimulatory molecules in tumor immunity. However, little is known about the direct interaction between neutrophils and CD4 T cells with respect to systemic lupus erythematosus (SLE). We have previously shown that OX40L expressed by monocytes from SLE patients promote the differentiation of naïve and memory cells into IL21 secreting T cells that are able to help B cells1,2.Objectives:In this study, we investigate OX40L expression on neutrophils from SLE patients and contribution of these OX40L+neutrophils in SLE pathogenesis to modulation of the B cell helper role of CD4 T cells.Methods:Surface expression of co-stimulatory molecules (OX40L, ICOSL, GITRL, 4-1BBL) on neutrophils from SLE patients and healthy donors (HD) was measured by flow cytometry (FC). Neutrophils from HD were stimulated with TLR7 or TLR8 agonists and IFNα after 5 hours of culture, OX40L expression was measured by FC and Western Blotting. CD4 T cells were cultured with the stimulated neutrophils for 3 days. At the end of the co-culture, percentages of IL21-expressing T follicular (Tfh) and peripheral helper (Tph) cells measured by FC. These generated T cells were also cultured in the presence of memory B cells. After 5 days of co-culture, plasmablast generation and Ig levels were assessed by FC and ELISA, respectively. Inhibition of OX40-OX40L interaction in vitro was achieved using ISB 830, a novel anti-OX40 mAb currently used in clinical trials.Results:Among the co-stimulatory molecules tested, percentages of OX40L+neutrophils in SLE (n=54) were increased compared to HD (n=25)(mean + SD: HD = 1,34%±1.62 vs SLE = 4,53%±8.1; p=0.29). OX40L expression positively correlated with SLE disease activity score (SLEDAI) (p = 0,04; r = 0,31) and with anti-DNA antibodies (p= 0,04, r = 0,33). Of note, the percentage of OX40L+neutrophils was higher in anti-sm-RNP+patients (n=16, mean= 9%±9.8), compared to anti-sm-RNP-patients (n=27, mean = 1,4%±2.5; p = 0,02). The percentage of OX40L+neutrophils was higher in patients with class III or IV lupus nephritis, and inflammatory infiltrate within the kidney biopsy disclosed OX40L+neutrophils, in close contact with T cells. Neutrophils from HD express OX40L with TLR8 agonist, or IFNα priming followed by TLR7 agonist. When memory CD4 T cells were cultured in the presence of TLR8-stimulated neutrophils, the proportion of IL21-expressing Tfh (CXCR5+PD1+) and Tph (CXCR5-PD1hi) were increased, compared to culture with unstimulated neutrophils. This process was dependent on OX40-OX40L interactions, since in vitro treatment with the anti-OX40 blocking antibody ISB 830, inhibited the differentiation of memory T cells into Tfh and Tph. Both generated Tfh and Tph were able to promote the differentiation of memory B cells into Ig-secreting plasmablasts.Conclusion:Our results disclose an unprecedented phenomenon where cross-talk between TLR7/8-activated neutrophils and CD4 lymphocytes operates through OX40L-OX40 costimulation, and neutrophils promote the differentiation of pro-inflammatory Tfh and Tph, as well as IL21 production. Therefore, OX40L/OX40 should be considered as a potentially therapeutic axis in SLE patients.References:[1]Jacquemin et al. Immunity 2015;[2]Jacquemin et al. JCI Insight 2018Disclosure of Interests:Angela Pappalardo Grant/research support from: Ichnos Sciences, Elodie Wojciechowski: None declared, Itsaso Odriozola: None declared, Isabelle Douchet: None declared, Nathalie Merillon: None declared, Andrea Boizard-Moracchini: None declared, Pierre Duffau: None declared, Estibaliz Lazaro: None declared, Marie-Agnes Doucey Employee of: Ichnos Sciences, Lamine Mbow Employee of: Ichnos Sciences, Christophe Richez Consultant of: Abbvie, Amgen, Mylan, Pfizer, Sandoz and UCB., Patrick Blanco Grant/research support from: Ichnos Sciences
Collapse
|
15
|
Pompella L, Tirino G, Pappalardo A, Caterino M, Ventriglia A, Nacca V, Orditura M, Ciardiello F, De Vita F. Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. Int J Mol Sci 2020; 21:E2814. [PMID: 32316602 PMCID: PMC7215357 DOI: 10.3390/ijms21082814] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/08/2020] [Accepted: 04/14/2020] [Indexed: 12/24/2022] Open
Abstract
Pancreatic cancer represents one of the most lethal disease worldwide but still orphan of a molecularly driven therapeutic approach, although many genomic and transcriptomic classifications have been proposed over the years. Clinical heterogeneity is a hallmark of this disease, as different patients show different responses to the same therapeutic regimens. However, genomic analyses revealed quite a homogeneous disease picture, with very common mutations in four genes only (KRAS, TP53, CDKN2A, and SMAD4) and a long tail of other mutated genes, with doubtful pathogenic meaning. Even bulk transcriptomic classifications could not resolve this great heterogeneity, as many informations related to small cell populations within cancer tissue could be lost. At the same time, single cell analysis has emerged as a powerful tool to dissect intratumoral heterogeneity like never before, with possibility of generating a new disease taxonomy at unprecedented molecular resolution. In this review, we summarize the most relevant genomic, bulk and single-cell transcriptomic classifications of pancreatic cancer, and try to understand how novel technologies, like single cell analysis, could lead to novel therapeutic strategies for this highly lethal disease.
Collapse
Affiliation(s)
- Luca Pompella
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “L. Vanvitelli”, Via Pansini n. 5, 80131 Naples, Italy; (G.T.); (A.P.); (M.C.); (A.V.); (V.N.); (M.O.); (F.C.)
| | | | | | | | | | | | | | | | - Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “L. Vanvitelli”, Via Pansini n. 5, 80131 Naples, Italy; (G.T.); (A.P.); (M.C.); (A.V.); (V.N.); (M.O.); (F.C.)
| |
Collapse
|
16
|
Tirino G, Petrillo A, Pompella L, Pappalardo A, Laterza MM, Panarese I, Sabetta R, Franco R, Galizia G, Ciardiello F, De Vita F. Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report. Front Oncol 2020; 10:130. [PMID: 32128313 PMCID: PMC7039182 DOI: 10.3389/fonc.2020.00130] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2019] [Accepted: 01/24/2020] [Indexed: 01/26/2023] Open
Abstract
Background: The prognosis of patients with advanced gastric cancer remains overall poor despite some recent innovations and the development of new therapeutic approaches. Current European guidelines do not recommend any specific treatment for patients with advanced gastric cancer refractory to two or more previous chemotherapy regimens, making this setting "orphan." Immunotherapy is quickly evolving also for this malignancy even if with controversial results and the correct patient selection is still debated, especially for Western patients. The phase III ONO-4538-12 "ATTRACTION-2" represents the current landmark trial for the development of immunotherapy for pretreated Asian patients and led to the approval of Nivolumab in some Asian countries, while only previous phase trials are available for Caucasians. Complete radiological response is anecdotic and has never been described both in the pivotal trial both in the others with Western patients enrolled. Case presentation: We report two cases of heavily pretreated Western elderly patients with metastatic gastric cancer who experienced durable complete radiological response to Nivolumab "off label" (more than 20 months to date) in a clinical practice context. Molecular analysis of potential predictive factors has been performed (PD-L1, EBV, MSI, and TMB) on primary tumor sample. Conclusions: Despite the lack of evidence for Western patients and the controversial outcome with the use of checkpoint inhibitors in previous settings, immunotherapy may dramatically change the prognosis and the natural history of pretreated Western metastatic gastric cancer, in a correctly selected population. Microsatellite instability and tumor mutational burden may be reliable predictive factors also for Caucasians. There is an urgent need for a change in clinical practice also for this "orphan" patients and more efforts are needed in order to clarify the role of predictive factors for a correct patient selection and better chances of survival for this awful malignancy.
Collapse
Affiliation(s)
- Giuseppe Tirino
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Angelica Petrillo
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Luca Pompella
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Annalisa Pappalardo
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
| | | | - Iacopo Panarese
- Dipartimento di Salute Mentale e Fisica e Medicina Preventiva, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy
| | - Rosalaura Sabetta
- Dipartimento di Salute Mentale e Fisica e Medicina Preventiva, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy
| | - Renato Franco
- Dipartimento di Salute Mentale e Fisica e Medicina Preventiva, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy
| | - Gennaro Galizia
- Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Fortunato Ciardiello
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Ferdinando De Vita
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
| |
Collapse
|
17
|
Pellino A, Manai C, Merz V, Scartozzi M, Milella M, De Vita F, Antonuzzo L, Zichi C, Satolli MA, Panebianco M, Noventa S, Giordano G, Nappo F, Zecchetto C, Puzzoni M, Vaccaro V, Pappalardo A, Giommoni E, Melisi D, Lonardi S. Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.4_suppl.660] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
660 Background: In the NAPOLI I phase III trial, Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) showed better outcome compared to 5FU/LV in patients with metastatic Pancreatic Cancer (MPC) progressed to 1st- line gemcitabine-based therapy. Aim of this study is to explore the real-world efficacy and safety of 5FU/LV-nal-IRI by a compassionate use programme and to identify potential prognostic factors that could affect survival in this setting. Methods: This is a retrospective multi-center analysis including patients with MPC who received 5FU/LV-nal-IRI after failure of a gemcitabine-based therapy. Survival analyses were carried out by the Kaplan-Meier method. Univariate and multivariate analyses were performed by using the log-rank test and the Cox regression. Results: A total of 296 pts (median age, 69 years, range 30-82; 50% male; ECOG PS 0, 44%) were treated at 11 Italian institutions from June 2016 and November 2018. 34% of the pts have been previously resected on their primary tumor, and 76% received gemcitabine-nabpaclitaxel as 1st - line treatment. 5FU/LV-nal-IRI has been administered as 2nd - line in 72% of the pts, while in 23% of the cases as 3rd - line or more. The median OS was 7.1 months [95% confidence interval (CI) 6.1 - 8.1] and the median PFS was 3.3 months (95% CI 2.9 - 3.6). At six months, OS and PFS rate were 53.4% and 31.4% respectively. ORR was 12% and DCR was 40%. 52% of pts received more than 4 cycle with dose reduction in 148 pts (50%). Most common grade 3 toxicities were neutropenia (14%), diarrhea (11%), anemia (3%), nausea (3%), fatigue (3%), mucositis (2%) and vomiting (1%). Baseline characteristics associated with better OS were ECOG PS 0, normal CEA, neutrophil-to-lymphocyte ratio ≤5 and haemoglobin ≥11 g/dL. Conclusions: These real-world data confirm the efficacy and safety of 5FU/LV-nal-IRI in patients with MPC progressed to a gemcitabine-based therapy, with outcome comparable to NAPOLI-1 even in a less selected population and with more active 1st - line combination therapy. In this cohort, well known prognostic markers has been confirmed, as expected.
Collapse
Affiliation(s)
- Antonio Pellino
- Department of Clinical and Experimental Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - Chiara Manai
- Department of Clinical and Experimental Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - Valeria Merz
- Unit of Medical Oncology, University of Verona Hospital Trust, Verona, TN, Italy
| | - Mario Scartozzi
- Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy
| | - Michele Milella
- Medical Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", Naples, Italy
| | - Lorenzo Antonuzzo
- Medical Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - Clizia Zichi
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy
| | | | - Michele Panebianco
- Medical Oncology Unit, Clinical Cancer Center, IRCCS-AUSL di Reggio Emilia, Reggio Emilia, Italy
| | - Silvia Noventa
- Medical Oncology Unit, Casa di Cura Poliambulanza, Brescia, Italy
| | - Guido Giordano
- Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Oncologia Medica, San Giovanni Rotondo, Italy
| | - Floriana Nappo
- Department of Clinical and Experimental Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - Camilla Zecchetto
- Unit of Medical Oncology, University of Verona Hospital Trust, Verona, Italy
| | - Marco Puzzoni
- Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy
| | - Vanja Vaccaro
- Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Annalisa Pappalardo
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", Naples, Italy
| | - Elisa Giommoni
- Medical Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - Davide Melisi
- Medicine - Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy
| | - Sara Lonardi
- Department of Clinical and Experimental Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| |
Collapse
|
18
|
Petrillo A, Tirino G, Zito Marino F, Pompella L, Sabetta R, Panarese I, Pappalardo A, Caterino M, Ventriglia A, Laterza MM, Morgillo F, Orditura M, Ciardiello F, Franco R, De Vita F. Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population. Onco Targets Ther 2020; 13:867-876. [PMID: 32099391 PMCID: PMC6996223 DOI: 10.2147/ott.s229813] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Accepted: 01/10/2020] [Indexed: 12/24/2022] Open
Abstract
PURPOSE ATTRACTION-2 trial assessed the role of Nivolumab as a new standard treatment for Asian patients with pretreated metastatic gastric cancer (mGC). The aim of this analysis was to evaluate the safety and efficacy of Nivolumab in a real-life Western population, considering the lack of evidence to date. PATIENTS AND METHODS Patients progressed after ≥2 chemotherapy regimens and able to receive Nivolumab (3 mg/kg q14) were eligible for the analysis. RESULTS 16 patients received Nivolumab as third (81.3%) or fourth line (18.7%) from September 2017 to July 2019. The safety was in line with the literature and only one patient discontinued treatment due to persistent hematological toxicity. Overall response rate and disease control rate were 18.7% and 31.2%, respectively. Median duration of response was 5 months. With a median follow-up of 21 months, median OS was 6 months (7, 21 and 22 months in the responders) and median PFS 3 months. PD-L1 and microsatellite status were retrospectively collected in 12 patients. All the major responders were MSI, although no statistically significant difference in OS or PFS was observed according to molecular analysis. CONCLUSION Nivolumab is feasible and effective in Western patients with mGC. Further investigation is urgently needed also in non-Asians.
Collapse
Affiliation(s)
- Angelica Petrillo
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Giuseppe Tirino
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Federica Zito Marino
- Pathology Unit, University of Study of Campania “Luigi Vanvitelli”, Naples80138, Italy
| | - Luca Pompella
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Rosalaura Sabetta
- Pathology Unit, University of Study of Campania “Luigi Vanvitelli”, Naples80138, Italy
| | - Iacopo Panarese
- Pathology Unit, University of Study of Campania “Luigi Vanvitelli”, Naples80138, Italy
| | - Annalisa Pappalardo
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Marianna Caterino
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Anna Ventriglia
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Maria Maddalena Laterza
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Floriana Morgillo
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Michele Orditura
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Fortunato Ciardiello
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| | - Renato Franco
- Pathology Unit, University of Study of Campania “Luigi Vanvitelli”, Naples80138, Italy
| | - Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples80131, Italy
| |
Collapse
|
19
|
Petrillo A, Pappalardo A, Calabrese F, Tirino G, Pompella L, Ventriglia J, Laterza MM, Caterino M, Sforza V, Iranzo V, Biglietto M, Orditura M, Ciardiello F, Conzo G, Molino C, De Vita F. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. J Gastrointest Oncol 2019; 10:910-917. [PMID: 31602329 DOI: 10.21037/jgo.2019.06.02] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the elderly as first-line treatment for mPC. Methods We retrospectively analyzed the data of 64 mPC patients (≥65 years old) treated according to the MPACT schedule. Results Median age was 69.5 years (range, 65-80 years); after a median of 5 cycles administered (range, 1-12), the most common adverse events (AEs) were grade 2 alopecia (46.9%), anemia (17.2%) and hypertransaminasemia (10.9%); all grades neutropenia occurred in 20.3% of pts. Global incidence of grade 3 and 4 toxicities were 26.5% and 0%, respectively, and no patients stopped treatment due to unacceptable toxicity. Stable disease (SD) was observed in 31.2% of patients, with a disease control rate (DCR) and overall response rate of 57.8% and 26.6%, respectively. After a median follow-up of 18 months, median progression free survival (PFS) was 8 months (95% CI: 6.3-9.6) and median OS was 12.0 months (95% CI: 8.4-15.6). The univariate analysis for overall survival (OS) showed that only ECOG performance status was an independent prognostic factor for survival. Conclusions Nab-paclitaxel plus gemcitabine schedule is feasible and effective in the "daily clinical practice" geriatric population.
Collapse
Affiliation(s)
- Angelica Petrillo
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | - Annalisa Pappalardo
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | | | - Giuseppe Tirino
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | - Luca Pompella
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | - Jole Ventriglia
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | - Maria Maddalena Laterza
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | - Marianna Caterino
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | - Vincenzo Sforza
- Medical Oncology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
| | - Vega Iranzo
- Medical Oncology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
| | - Maria Biglietto
- Division of Medical Oncology, AORN, "A Cardarelli", Napoli, Italy
| | - Michele Orditura
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | - Fortunato Ciardiello
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| | - Giovanni Conzo
- Department of Cardiothoracic Sciences, University of study of Campania "L. Vanvitelli", Naples, Italy
| | - Carlo Molino
- Division of General Surgery, AORN, "A. Cardarelli", Napoli, Italy
| | - Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, University of study of Campania "L. Vanvitelli", Napoli, Italy
| |
Collapse
|
20
|
Petrillo A, Pappalardo A, Pompella L, Tirino G, Calabrese F, Laterza MM, Caterino M, Ventriglia A, Orditura M, Conzo G, Molino C, Ciardiello F, Biglietto M, De Vita F. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Med Oncol 2019; 36:83. [PMID: 31444639 DOI: 10.1007/s12032-019-1306-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2019] [Accepted: 08/15/2019] [Indexed: 12/27/2022]
Abstract
Nab-paclitaxel plus gemcitabine (Nab-Gem) represents one of the standard regimen for first-line treatment of metastatic pancreatic adenocarcinoma (mPDAC). However, few data are available in mPDAC relapsed after gemcitabine as adjuvant treatment. Our study aims to evaluate the efficacy and feasibility of Nab-Gem as first-line treatment for mPDAC patients previously treated with adjuvant treatment. We retrospectively analyzed the safety and efficacy data of 36 patients, who received first-line Nab-Gem after gemcitabine as adjuvant treatment. All patients received gemcitabine after radical surgery. Median disease-free survival was 12 months (95% CI 9.7-14.3); at relapse, all patients received Nab-Gem. We observed an objective response rate and disease control rate of 11.1% and 63.9%, respectively. With a median follow-up of 47 months, median progression-free survival was 5 months (95% CI 1.0-9.0), whereas median overall survival (OS) was 13 months (95% CI 5.5-20.5). Median OS was higher in patients with a relapse ≥ 7 months after the end of adjuvant treatment than in patients relapsed < 7 months (14 vs. 8 months, respectively, p: 0.52). Our results show that first-line Nab-Gem is feasible and effective in patients previously treated with gemcitabine as adjuvant treatment.
Collapse
Affiliation(s)
- Angelica Petrillo
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy.
| | - Annalisa Pappalardo
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy
| | - Luca Pompella
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy
| | - Giuseppe Tirino
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy
| | | | - Maria Maddalena Laterza
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy
| | - Marianna Caterino
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy
| | - Anna Ventriglia
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy
| | - Michele Orditura
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy
| | - Giovanni Conzo
- Department of Cardiothoracic Sciences, University of Study of Campania "L. Vanvitelli", Via Sergio Pansini 5, 80131, Naples, Italy
| | - Carlo Molino
- Department of Oncological Surgery, A.O.R.N. "A. Cardarelli", Naples, Italy
| | - Fortunato Ciardiello
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy
| | - Maria Biglietto
- Division of Medical Oncology, AORN, "A Cardarelli", Naples, Italy
| | - Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania "L. Vanvitelli", via Pansini n.5, 80131, Naples, Italy.
| |
Collapse
|
21
|
Petrillo A, Laterza MM, Tirino G, Pompella L, Pappalardo A, Ventriglia J, Savastano B, Auricchio A, Orditura M, Ciardiello F, Galizia G, De Vita F. Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. J Gastrointest Oncol 2019; 10:314-323. [PMID: 31032100 DOI: 10.21037/jgo.2018.12.06] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Background Neoangiogenesis has proven to be a relevant pathogenetic mechanism in gastric cancer (GC) and lymphatic spread represents an important well-known prognostic factor. Vascular endothelial growth factor C (VEGF-C) plays a key role in lymphangiogenesis and its blood levels in GC patients are easily measurable. This analysis aimed to investigate the prognostic role of preoperative VEGF-C blood levels. Methods VEGF-C serum levels were determined by enzyme-linked immunoadsorbent assay (ELISA) in 186 patients observed at our institution from January 2004 until December 2009 and 82 healthy subjects. Statistical analyses were performed using SPSS 21.0. Results VEGF-C levels were significantly higher in GC patients (median: 287.4 pg/mL; range, 76.2-865.2 pg/mL) than in the control group (median VEGF-C: 31 pg/mL; range, 12-97 pg/mL). A significant correlation between VEGF-C levels, T, N and tumor stage has been described. The median overall survival (OS) was statistically significantly higher in pts with low serum VEGF-C levels [median: not reached (NR) vs. 26 months; P<0.0001]. Higher preoperative VEGF-C levels correlated also with earlier disease relapse and poor disease-free survival (DFS) (median NR in each subgroup, P=0.005). Furthermore, high VEGF-C levels [hazard ratio (HR) =2.7; P=0.018] and tumor grading (HR =0.44; P=0.007) were independent prognostic factors for OS at multivariate analysis. Conclusions Our study showed that increased VEGF-C levels are significantly associated with advanced regional lymph node involvement and poor OS and DFS in pts with resected GC paving the way to a possible application as prognostic factor in the clinical practice.
Collapse
Affiliation(s)
- Angelica Petrillo
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Maria Maddalena Laterza
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Giuseppe Tirino
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Luca Pompella
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Annalisa Pappalardo
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Jole Ventriglia
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Beatrice Savastano
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Annamaria Auricchio
- Division of GI Tract Surgical Oncology, Department of Cardio-Thoracic and Respiratory Sciences, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Michele Orditura
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Fortunato Ciardiello
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Gennaro Galizia
- Division of GI Tract Surgical Oncology, Department of Cardio-Thoracic and Respiratory Sciences, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| |
Collapse
|
22
|
Franzese I, Biagio LS, Gatti G, Perrotti A, Mariscalco G, Milano A, De Feo M, Rubino A, Santarpino G, Salsano A, Lucarelli C, Francica A, Beghi C, Mignosa C, Pappalardo A, D’Errigo P, Santini F, Onorati F, Faggian G. OC62 REDO MITRAL SURGERY AND HOSPITAL OUTCOME. J Cardiovasc Med (Hagerstown) 2018. [DOI: 10.2459/01.jcm.0000549859.74998.9b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
23
|
Franzese I, Biagio LS, Perrotti A, Mariscalco G, Francica A, Lucarelli C, De Feo M, Santarpino G, Salsano A, Rubino A, Gatti G, Beghi C, Mignosa C, Pappalardo A, Onorati F, Santini F, Faggian G. RF67 REDO MITRAL SURGERY AND HOSPITAL OUTCOME. J Cardiovasc Med (Hagerstown) 2018. [DOI: 10.2459/01.jcm.0000550012.26990.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
24
|
Cimino V, Chisari CG, Raciti G, Pappalardo A, Zappia M, Patti F. Static postural control disturbances among the different multiple sclerosis phenotypes: A Neurocom Balance Manager ® evaluation study. Mult Scler Relat Disord 2018; 26:46-51. [PMID: 30223228 DOI: 10.1016/j.msard.2018.08.024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2018] [Revised: 08/03/2018] [Accepted: 08/23/2018] [Indexed: 11/25/2022]
Abstract
BACKGROUND The computerized stabilometric platform can be used and privileged over clinical scales, as self-administered questionnaires to asses postural control and balance evaluation in Multiple sclerosis (MS). Aim of our study was to evaluate static postural control assessed by Neurocom Balance Manager® through the modified Clinical Test of Sensory Interaction on Balance (mCTSIB) in relapsing-remitting MS (RRMS), progressive MS (PMS) and CIS, compared to healthy controls (HC). METHODS We screened MS patients consecutively referring to our MS Center at University of Catania, during July 2013-June 2014 diagnosed as CIS, RRMS and PMS. All MS patients underwent clinical and neurological evaluations and a complete postural exam by Neurocom Balance Manager® in order to evaluate Center of Pressure (COP), through mCTSIB. We evaluated the following parameters: Total Path Length-open eyes (TPL-OE), Total Path Length-closed eyes (TPL-CE), Sway Area-open eyes (SA-OE), Sway Area-closed eyes (SA-CE), Mean sway velocity-open eyes (MSV-OE), Mean sway velocity-closed eyes (MSV-CE). Additionally, patients were tested by Berg balance scale (BBS) for balance and Barthel Index (BI) for disability outcomes. RESULTS Out of 170 MS patients assessed for eligibility, 163 met the inclusion/exclusion criteria and were finally enrolled. All balance parameters were found more impaired in MS group compared to controls and CIS. Moreover, no differences in terms of balance assessment were found between HC and CIS. The correlation analysis showed that BBS was strongly associated to SA-OE, SA-CE, TPL-OE and MSV-OE. We also found a correlation between BI and SA-CE. CONCLUSION Our study revealed significant differences among HCs, CIS and MS. MS, especially PMS, exhibit the worst balance performances especially in EC trials. The higher correlation between balance parameters, especially sway area, and BBS score confirmed the reliability and sensibility of mCTSIB assessment in evaluating static postural control in MS patients.
Collapse
Affiliation(s)
- V Cimino
- Centro Neurolesi "Bonino Pulejo", IRCSS, Messina, Italy
| | - C G Chisari
- Department G.F. Ingrassia, section of Neuroscience, University of Catania, Via S. Sofia n°78, Catania 95123, Italy
| | - G Raciti
- Centro Neurolesi "Bonino Pulejo", IRCSS, Messina, Italy
| | - A Pappalardo
- Department of Rehabilitation, S.Marta & S.Venera Hospital, Acireale, Catania, Italy
| | - M Zappia
- Department G.F. Ingrassia, section of Neuroscience, University of Catania, Via S. Sofia n°78, Catania 95123, Italy
| | - F Patti
- Department G.F. Ingrassia, section of Neuroscience, University of Catania, Via S. Sofia n°78, Catania 95123, Italy.
| |
Collapse
|
25
|
Tirino G, Pompella L, Petrillo A, Laterza MM, Pappalardo A, Caterino M, Orditura M, Ciardiello F, Galizia G, De Vita F. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. Int J Mol Sci 2018; 19:E2659. [PMID: 30205505 PMCID: PMC6165492 DOI: 10.3390/ijms19092659] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2018] [Revised: 09/03/2018] [Accepted: 09/05/2018] [Indexed: 02/05/2023] Open
Abstract
Despite some remarkable innovations and the advent of novel molecular classifications the prognosis of patients with advanced gastric cancer (GC) remains overall poor and current clinical application of new advances is disappointing. During the last years only Trastuzumab and Ramucirumab have been approved and currently used as standard of care targeted therapies, but the systemic management of advanced disease did not radically change in contrast with the high number of molecular drivers identified. The Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) classifications paved the way, also for GC, to that more contemporary therapeutic approach called "precision medicine" even if tumor heterogeneity and a complex genetic landscape still represent a strong barrier. The identification of specific cancer subgroups is also making possible a better selection of patients that are most likely to respond to immunotherapy. This review aims to critically overview the available molecular classifications summarizing the main druggable molecular drivers and their possible therapeutic implications also taking advantage of new technologies and acquisitions.
Collapse
Affiliation(s)
- Giuseppe Tirino
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Luca Pompella
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Angelica Petrillo
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Maria Maddalena Laterza
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Annalisa Pappalardo
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Marianna Caterino
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Michele Orditura
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Fortunato Ciardiello
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Gennaro Galizia
- Division of GI Tract Surgical Oncology, Department of Cardio-Thoracic and Respiratory Sciences, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| | - Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "Luigi Vanvitelli", Via Pansini n.5, 80131 Naples, Italy.
| |
Collapse
|
26
|
Petrillo A, Laterza MM, Tirino G, Pompella L, Ventriglia J, Pappalardo A, Famiglietti V, Martinelli E, Ciardiello F, Orditura M, Galizia G, De Vita F. Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. Future Oncol 2018; 14:2493-2505. [PMID: 29969285 DOI: 10.2217/fon-2018-0167] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
AIM Systemic inflammatory response affects survival of gastric cancer (GC) patients. This study was carried out to create a prognostic inflammatory-based score to predict survival in metastatic GC (mGC) before first-line chemotherapy. MATERIALS & METHODS We studied the prognostic value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio in 151 patients with mGC at the diagnosis. RESULTS Median overall survival (OS) was significantly lower in patients with high NLR. Performance status 1-2 according to the Eastern Cooperative Oncology Group scale and NLR were predictors of shorter OS at multivariate analysis. Based on these results, we defined a prognostic OS score, showing a better median OS in favorable risk group. CONCLUSION Elevated pretreatment NLR and Eastern Cooperative Oncology Group are independent predictors of shorter OS in mGC patients before first-line chemotherapy.
Collapse
Affiliation(s)
- Angelica Petrillo
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Maria Maddalena Laterza
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Giuseppe Tirino
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Luca Pompella
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Jole Ventriglia
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Annalisa Pappalardo
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Vincenzo Famiglietti
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Erika Martinelli
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Fortunato Ciardiello
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Michele Orditura
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| | - Gennaro Galizia
- University of Campania 'Luigi Vanvitelli'- Division of GI Tract Surgical Oncology, Department of Surgical Sciences, Via Pansini n.5, 80131 Naples, Italy
| | - Ferdinando De Vita
- University of Campania 'Luigi Vanvitelli' - School of Medicine, Department of Precision Medicine, Division of Medical Oncology, Via Pansini n.5, 80131 Naples, Italy
| |
Collapse
|
27
|
Shin J, Abaci H, Guo Z, Magrelli F, Pappalardo A, Doucet Y, Jackow J, Christiano A. 1448 Development of immune-competent human skin constructs to model inflammatory skin diseases. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.1466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
28
|
Laterza MM, Pompella L, Petrillo A, Tirino G, Pappalardo A, Orditura M, Troiani T, Ciardiello F, Di Martino N, De Vita F. Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. Med Oncol 2017; 34:186. [DOI: 10.1007/s12032-017-1046-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Accepted: 10/13/2017] [Indexed: 11/30/2022]
|
29
|
Petrillo A, Laterza M, Ventriglia J, Savastano B, Tirino G, Pompella L, Pappalardo A, Orditura M, Ciardello F, De Vita F. HER2 negative metastatic gastric cancer (mGC): a retrospective analysis on the efficacy of doublet or triplet chemotherapy (CT) as a first-line therapy in the clinical practice. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Laterza M, Ciaramella V, Morgillo F, Belli V, Petrillo A, Tirino G, Pompella L, Savastano B, Pappalardo A, Orditura M, Ciardiello F, De Vita F. Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Ventriglia J, Laterza M, Savastano B, Petrillo A, Tirino G, Pompella L, Pappalardo A, Orditura M, Ciardiello F, De Vita F. Gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis on the efficacy and safety profile. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Ventriglia J, Laterza M, Savastano B, Petrillo A, Tirino G, Pompella L, Pappalardo A, Orditura M, Ciardiello F, De Vita F. Safety and efficacy of gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.139] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Laterza M, Ciaramella V, Morgillo F, Belli V, Tirino G, Pompella L, Petrillo A, Savastano B, Pappalardo A, Orditura M, Ciardiello F, De Vita F. Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Barbagallo M, Musumarra A, Cosentino L, Maugeri E, Heinitz S, Mengoni A, Dressler R, Schumann D, Käppeler F, Colonna N, Finocchiaro P, Ayranov M, Damone L, Kivel N, Aberle O, Altstadt S, Andrzejewski J, Audouin L, Bacak M, Balibrea-Correa J, Barros S, Bécares V, Bečvář F, Beinrucker C, Berthoumieux E, Billowes J, Bosnar D, Brugger M, Caamaño M, Calviani M, Calviño F, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Cerutti F, Chen YH, Chiaveri E, Cortés G, Cortés-Giraldo MA, Cristallo S, Diakaki M, Domingo-Pardo C, Dupont E, Duran I, Fernandez-Dominguez B, Ferrari A, Ferreira P, Furman W, Ganesan S, García-Rios A, Gawlik A, Glodariu T, Göbel K, Gonçalves IF, González-Romero E, Griesmayer E, Guerrero C, Gunsing F, Harada H, Heftrich T, Heyse J, Jenkins DG, Jericha E, Katabuchi T, Kavrigin P, Kimura A, Kokkoris M, Krtička M, Leal-Cidoncha E, Lerendegui J, Lederer C, Leeb H, Lo Meo S, Lonsdale SJ, Losito R, Macina D, Marganiec J, Martínez T, Massimi C, Mastinu P, Mastromarco M, Mazzone A, Mendoza E, Milazzo PM, Mingrone F, Mirea M, Montesano S, Nolte R, Oprea A, Pappalardo A, Patronis N, Pavlik A, Perkowski J, Piscopo M, Plompen A, Porras I, Praena J, Quesada J, Rajeev K, Rauscher T, Reifarth R, Riego-Perez A, Rout P, Rubbia C, Ryan J, Sabate-Gilarte M, Saxena A, Schillebeeckx P, Schmidt S, Sedyshev P, Smith AG, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Vollaire J, Wallner A, Warren S, Weigand M, Weiß C, Wolf C, Woods PJ, Wright T, Žugec P. ^{7}Be(n,α)^{4}He Reaction and the Cosmological Lithium Problem: Measurement of the Cross Section in a Wide Energy Range at n_TOF at CERN. Phys Rev Lett 2016; 117:152701. [PMID: 27768364 DOI: 10.1103/physrevlett.117.152701] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2016] [Indexed: 06/06/2023]
Abstract
The energy-dependent cross section of the ^{7}Be(n,α)^{4}He reaction, of interest for the so-called cosmological lithium problem in big bang nucleosynthesis, has been measured for the first time from 10 meV to 10 keV neutron energy. The challenges posed by the short half-life of ^{7}Be and by the low reaction cross section have been overcome at n_TOF thanks to an unprecedented combination of the extremely high luminosity and good resolution of the neutron beam in the new experimental area (EAR2) of the n_TOF facility at CERN, the availability of a sufficient amount of chemically pure ^{7}Be, and a specifically designed experimental setup. Coincidences between the two alpha particles have been recorded in two Si-^{7}Be-Si arrays placed directly in the neutron beam. The present results are consistent, at thermal neutron energy, with the only previous measurement performed in the 1960s at a nuclear reactor. The energy dependence reported here clearly indicates the inadequacy of the cross section estimates currently used in BBN calculations. Although new measurements at higher neutron energy may still be needed, the n_TOF results hint at a minor role of this reaction in BBN, leaving the long-standing cosmological lithium problem unsolved.
Collapse
Affiliation(s)
| | - A Musumarra
- Dipartimento di Fisica e Astronomia DFA, Università di Catania, Italy
- INFN-Laboratori Nazionali del Sud, Catania, Italy
| | - L Cosentino
- INFN-Laboratori Nazionali del Sud, Catania, Italy
| | - E Maugeri
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | - S Heinitz
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | | | - R Dressler
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | - D Schumann
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | - F Käppeler
- Karlsruhe Institute of Technology (KIT), Institut für Kernphysik, Karlsruhe, Germany
| | | | | | - M Ayranov
- European Commission, DG-Energy, Luxembourg
| | | | - N Kivel
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | | | - S Altstadt
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | | | - L Audouin
- Centre National de la Recherche Scientifique/IN2P3-IPN, Orsay, France
| | - M Bacak
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | - J Balibrea-Correa
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - S Barros
- C2TN-Instituto Superior Tecníco, Universidade de Lisboa, Portugal
| | - V Bécares
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - F Bečvář
- Charles University, Prague, Czech Republic
| | - C Beinrucker
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | | | - J Billowes
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - D Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Croatia
| | | | - M Caamaño
- Universidade de Santiago de Compostela, Spain
| | | | - F Calviño
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | - D Cano-Ott
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R Cardella
- INFN-Laboratori Nazionali del Sud, Catania, Italy
- CERN, Geneva, Switzerland
| | - A Casanovas
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | | | | | - Y H Chen
- Centre National de la Recherche Scientifique/IN2P3-IPN, Orsay, France
| | | | - G Cortés
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | | | - S Cristallo
- INAF-Osservatorio Astronomico di Collurania, Teramo, Italy
| | - M Diakaki
- National Technical University of Athens (NTUA), Greece
| | - C Domingo-Pardo
- Instituto de Física Corpuscular, CSIC-Universidad de Valencia, Spain
| | - E Dupont
- CEA/Saclay-IRFU, Gif-sur-Yvette, France
| | - I Duran
- Universidade de Santiago de Compostela, Spain
| | | | | | - P Ferreira
- C2TN-Instituto Superior Tecníco, Universidade de Lisboa, Portugal
| | - W Furman
- Joint Institute of Nuclear Research, Dubna, Russia
| | - S Ganesan
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - A García-Rios
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Gawlik
- Uniwersytet Łódzki, Lodz, Poland
| | - T Glodariu
- Horia Hulubei National Institute of Physics and Nuclear Engineering-IFIN HH, Bucharest-Magurele, Romania
| | - K Göbel
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - I F Gonçalves
- C2TN-Instituto Superior Tecníco, Universidade de Lisboa, Portugal
| | - E González-Romero
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - E Griesmayer
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | | | - F Gunsing
- CEA/Saclay-IRFU, Gif-sur-Yvette, France
| | - H Harada
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - T Heftrich
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - J Heyse
- European Commission JRC, Institute for Reference Materials and Measurements, Retieseweg 111, B-2440 Geel, Belgium
| | - D G Jenkins
- University of York, Heslington, York, United Kingdom
| | - E Jericha
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | | | - P Kavrigin
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | - A Kimura
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - M Kokkoris
- National Technical University of Athens (NTUA), Greece
| | - M Krtička
- Charles University, Prague, Czech Republic
| | | | | | - C Lederer
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - H Leeb
- Atominstitut der Österreichischen Universitäten, Technis che Universität Wien, Austria
| | - S Lo Meo
- ENEA, Bologna, Italy
- INFN, Sezione di Bologna, Italy
| | - S J Lonsdale
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | | | | | | | - T Martínez
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - C Massimi
- INFN, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna
| | - P Mastinu
- INFN-Laboratori Nazionali di Legnaro, Italy
| | | | - A Mazzone
- INFN, Sezione di Bari, Italy
- CNR-IC, Bari, Italy
| | - E Mendoza
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | | | - F Mingrone
- INFN, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna
| | - M Mirea
- Horia Hulubei National Institute of Physics and Nuclear Engineering-IFIN HH, Bucharest-Magurele, Romania
| | | | - R Nolte
- Physikalisch Technische Bundesanstalt (PTB), Braunschweig, Germany
| | - A Oprea
- Horia Hulubei National Institute of Physics and Nuclear Engineering-IFIN HH, Bucharest-Magurele, Romania
| | - A Pappalardo
- INFN-Laboratori Nazionali del Sud, Catania, Italy
| | | | - A Pavlik
- University of Vienna, Faculty of Physics, Austria
| | | | - M Piscopo
- INFN-Laboratori Nazionali del Sud, Catania, Italy
| | - A Plompen
- European Commission JRC, Institute for Reference Materials and Measurements, Retieseweg 111, B-2440 Geel, Belgium
| | | | - J Praena
- Universidad de Sevilla, Spain
- Universidad de Granada, Spain
| | | | - K Rajeev
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - T Rauscher
- Centre for Astrophysics Research, School of Physics, Astronomy and Mathematics, University of Hertfordshire, Hatfield, United Kingdom
- Department of Physics, University of Basel, Basel, Switzerland
| | - R Reifarth
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - A Riego-Perez
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | - P Rout
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | | | - J Ryan
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | | | - A Saxena
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - P Schillebeeckx
- European Commission JRC, Institute for Reference Materials and Measurements, Retieseweg 111, B-2440 Geel, Belgium
| | - S Schmidt
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - P Sedyshev
- Joint Institute of Nuclear Research, Dubna, Russia
| | - A G Smith
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | | | | | - J L Tain
- Instituto de Física Corpuscular, CSIC-Universidad de Valencia, Spain
| | | | - L Tassan-Got
- Centre National de la Recherche Scientifique/IN2P3-IPN, Orsay, France
| | | | - S Valenta
- Charles University, Prague, Czech Republic
| | - G Vannini
- INFN, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna
| | | | - P Vaz
- C2TN-Instituto Superior Tecníco, Universidade de Lisboa, Portugal
| | | | | | - R Vlastou
- National Technical University of Athens (NTUA), Greece
| | | | - A Wallner
- University of Vienna, Faculty of Physics, Austria
- Research School of Physics and Engineering, Australian National University, ACT 0200, Australia
| | - S Warren
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - M Weigand
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - C Weiß
- CERN, Geneva, Switzerland
| | - C Wolf
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - P J Woods
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - T Wright
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - P Žugec
- Department of Physics, Faculty of Science, University of Zagreb, Croatia
| |
Collapse
|
35
|
Pappalardo A, Albakri A, Liu C, Bascetta L, De Momi E, Poignet P. Hunt–Crossley model based force control for minimally invasive robotic surgery. Biomed Signal Process Control 2016. [DOI: 10.1016/j.bspc.2016.05.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Abstract
Alien hand syndrome (AHS) is a rare syndrome characterized by involuntary, uncontrollable, and purposeless movement of one upper limb, which is considered as extraneous by the patient. The term AHS was previously used to describe a syndrome due to lesions in the anterior corpus callosum. Successively, some authors reported cases of AHS in patients due to posterior cerebral lesions, without lesions of the corpus callosum. Thus, it was possible to distinguish the posterior variant of AHS from the anterior form. The authors report an unusual case of posterior AHS due to a unique parieto-occipital lesion of the dominant hemisphere. However, the patient showed clinical findings that were similar to the anterior AHS. The rehabilitative treatment, individualized and targeted toward the specific needs of the patient, allowed the improvement of the patient’s participation in activities of daily living.
Collapse
Affiliation(s)
- A Pappalardo
- Dipartimento di Scienze Neurologiche, Università di Catania, Azienda Policlinico-Edificio 20, Via S. Sofia 78, Italy.
| | | | | | | |
Collapse
|
37
|
Cosentino L, Musumarra A, Barbagallo M, Colonna N, Damone L, Pappalardo A, Piscopo M, Finocchiaro P. Silicon detectors for monitoring neutron beams in n-TOF beamlines. Rev Sci Instrum 2015; 86:073509. [PMID: 26233385 DOI: 10.1063/1.4927073] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
During 2014, the second experimental area (EAR2) was completed at the n-TOF neutron beam facility at CERN (n-TOF indicates neutron beam measurements by means of time of flight technique). The neutrons are produced via spallation, by means of a high-intensity 20 GeV pulsed proton beam impinging on a thick target. The resulting neutron beam covers the energy range from thermal to several GeV. In this paper, we describe two beam diagnostic devices, both exploiting silicon detectors coupled with neutron converter foils containing (6)Li. The first one is based on four silicon pads and allows monitoring of the neutron beam flux as a function of the neutron energy. The second one, in beam and based on position sensitive silicon detectors, is intended for the reconstruction of the beam profile, again as a function of the neutron energy. Several electronic setups have been explored in order to overcome the issues related to the gamma flash, namely, a huge pulse present at the start of each neutron bunch which may blind the detectors for some time. The two devices were characterized with radioactive sources and also tested at the n-TOF facility at CERN. The wide energy and intensity range they proved capable of sustaining made them attractive and suitable to be used in both EAR1 and EAR2 n-TOF experimental areas, where they became immediately operational.
Collapse
Affiliation(s)
- L Cosentino
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - A Musumarra
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | | | | | - L Damone
- INFN Sezione di Bari, Bari, Italy
| | - A Pappalardo
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - M Piscopo
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | | |
Collapse
|
38
|
Santarpino G, Dalén M, Biancari F, Rubino A, De Praetere H, Kasama K, Deste W, Pollari F, Meuris B, Mignosa C, Gatti G, Pappalardo A, Sartipy U, Svenarud P, Fischlein T. Ministernotomy versus Full Sternotomy Aortic Valve Replacement with a Sutureless Aortic Bioprosthesis: An European Multicenter Registry. Thorac Cardiovasc Surg 2015. [DOI: 10.1055/s-0035-1544254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Pappalardo A, Ciancio M, Patti F. Is the basic trunk control recovery different between stroke patients with right and left hemiparesis? NeuroRehabilitation 2014; 35:215-20. [DOI: 10.3233/nre-141109] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- A. Pappalardo
- Physical Medicine and Rehabilitation Center, Ospedale S. Marta & S. Venera, Acireale, Catania, Italy
- Departement of Neuroscience, University of Catania, Catania, Italy
| | - M.R. Ciancio
- Physical Medicine and Rehabilitation Center, Ospedale S. Pietro, Caltagirone, Catania, Italy
| | - F. Patti
- Departement of Neuroscience, University of Catania, Catania, Italy
| |
Collapse
|
40
|
Rufa M, Antonitsis P, Winkler B, Kiessling AH, Ulrich C, Bennett MJ, Kehara H, Asopa S, Alexopoulos C, Zavaropoulos P, Alexopoulos C, Ganushchak YM, McLean LA, Borrelli U, Antonitsis P, Gifford D, Reineke D, Antonitsis P, Bennett M, Schubel J, Schubel J, Ulrich C, Schaarschmidt J, Tiliscan C, Bauer A, Hausmann H, Asteriou C, Argiriadou H, Deliopoulos A, Gatzos S, Anastasiadis K, Zenklusen U, Döbele T, Kohler B, Grapow M, Eckstein F, May M, Keller H, Diefenbach M, Reyher C, Moritz A, Bauer A, Eberle T, Schaarschmidt J, Lucy J, Hausmann H, Larsen M, Asopa S, Webb G, Wright A, Lloyd C, Takano T, Fujii T, Gomibuchi T, Nakahara K, Ohhashi N, Komatsu K, Ohtsu Y, Terasaki T, Wada Y, Seto T, Fukui D, Amano J, Bennett M, Webb G, Lloyd C, Hakim N, Zografos P, Protopapas E, Zavaropoulos P, Kirvassilis G, Sarris G, Alexopoulos C, Hakim N, Zografos P, Protopapas E, Kirvassilis G, Sarris G, Hakim N, Zografos P, Protopapas E, Zavaropoulos P, Kirvassilis G, Sarris G, Körver E, Yamamoto Y, Weerwind P, Medlam W, Bell J, Bennett R, Bennett R, Turner E, Jagannadham K, Westwood E, Silvestri A, Detroux M, Nottin R, Al-Attar N, Pappalardo A, Gabrielli M, Gripari C, Scala A, Mercurio S, Gustin G, Fasolo D, Deliopoulos A, Gatzos S, Mimikos S, Kleontas A, Grosomanidis V, Kyparissa M, Tossios P, Anastasiadis K, Colah S, Farid S, Irons J, Gilhouly M, Moorjani N, König T, Meszaros K, Sodeck G, Erdoes G, Englberger L, Czerny M, Carrel T, Mimikos S, Kostarelou G, Kleontas A, Deliopoulos A, Gatzos S, Foroulis C, Tossios P, Anastasiadis K, Asopa S, Webb G, Gomez-Cano M, Lloyd C, Xhymshiti A, Ulrich C, Schaarschmidt J, Eberle T, Rufa M, Bauer A, Hausmann H. 1st International Symposium on Minimal Invasive Extracorporeal Circulation Technologies, Thessaloniki, Greece, 13–14 June 2014001EMERGENCY CORONARY ARTERY BYPASS GRAFT SURGERY IN PATIENTS WITH OR WITHOUT ACUTE MYOCARDIAL INFARCTION USING THE MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION002IS THERE A LEARNING CURVE WHEN USING MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION IN CORONARY REVASCULARIZATION PROCEDURES?003MINIMAL EXTRACORPOREAL CIRCULATION ASSURES PERFORMANCE OUTCOME004CORONARY ARTERY REVASCULARIZATION WITH A MINIMAL EXTRACORPOREAL CIRCULATION TECHNIQUE: SHOTGUN ANALYSIS IN A PROSPECTIVE, RANDOMIZED TRIAL WITH THREE DIFFERENT PERFUSION TECHNIQUES005EFFECTS OF CELL SALVAGED AND DIRECTLY RETRANSFUSED MEDIASTINAL SHED BLOOD ON THE POSTOPERATIVE COMPETENCY OF THE COAGULATION SYSTEM AFTER CORONARY ARTERY BYPASS GRAFT SURGERY006THE RELATIVE INFLUENCE OF MINIATURIZED CARDIOPULMONARY BYPASS AND OTHER PERIOPERATIVE FACTORS ON BLOOD TRANSFUSION REQUIREMENT AFTER HEART SURGERY007LOWER PLATELET AGGREGATION MIGHT REDUCE PERIOPERATIVE BLEEDING IN MINI-CIRCUIT CARDIOPULMONARY BYPASS COMPARED TO CONVENTIONAL CARDIOPULMONARY BYPASS0085-YEAR EXPERIENCE OF BLOOD TRANSFUSION IN CORONARY ARTERY BYPASS GRAFT SURGERY PATIENTS USING MINIATURIZED EXTRACORPOREAL CIRCULATION009PAEDIATRIC CARDIAC EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: IMPROVED OUTCOME WITH EVOLVING TECHNOLOGY AND PRACTICE REFINEMENTS OVER 16 YEARS010THE USE OF ARTERIOVENOUS PCO 2DIFFERENCE (Delta PCO 2) AS AN INDEX OF THE DENSITY OF CAPILLARY PERFUSION DURING PAEDIATRIC CARDIOPULMONARY BYPASS AND EXTRACORPOREAL MEMBRANE OXYGENATION011‘ETERNAL ECMO’: THE CHALLENGE OF PROLONGED POST-CARDIOTOMY EXTRACORPOREAL MEMBRANE OXYGENATION012A VERSATILE MINIMIZED SYSTEM: THE STEP TOWARDS SAFE PERFUSION013HOW WE DEVELOPED A SAFER MINI BYPASS SYSTEM WITH THE USE OF A STOCKERT HEART LUNG BYPASS MACHINE AND MEDTRONIC FUSION OXYGENATOR014MINIMALIZING THE CARDIOPULMONARY BYPASS CIRCUIT AND THE CONSOLE015IS THREE-STAGE VENOUS CANNULA SUPERIOR TO DUAL-STAGE DURING SURGERY WITH MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION?016BENEFITS OF CLOSED MINIATURIZED CARDIOPULMONARY BYPASS017COGNITIVE BRAIN FUNCTION AFTER CORONARY BYPASS GRAFTING WITH MINIMIMAL INVASIVE EXTRACORPOREAL CIRCULATION018MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION REDUCES GASEOUS MICROEMBOLI AND PRESERVES NEUROCOGNITIVE FUNCTION: A SINGLE-CENTRE PROSPECTIVE RANDOMIZED STUDY019THE INFLUENCE OF PERIOPERATIVE FACTORS TO GENERATE ‘OUTLIERS’ IN CARDIAC SURGERY ASSOCIATED ACUTE KIDNEY INJURY: A PRELIMINARY INVESTIGATION INCLUDING DIABETES AND METHOD OF CARDIOPULMONARY BYPASS020MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION IN 64 COMPLEX CARDIAC PROCEDURES: IS IT FEASIBLE AND SAFE? Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Russo L, Cosentino L, Pappalardo A, Piscopo M, Scirè C, Scirè S, Vecchio G, Muscato G, Finocchiaro P. A Robotic arm for optical and gamma radwaste inspection. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20137902007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
Tsang W, Salgo I, Gajjar M, Abduch M, Freed B, Weinert L, Lang R, Mordi I, Al-Attar N, Tzemos N, Cacicedo A, Velasco Del Castillo S, Anton Ladislao A, Aguirre Larracoechea U, Arana Achaga X, Zugazabeitia Irazabal G, Romero Pereiro A, Sadaba Sagredo M, Laraudogoitia Zaldumbide E, Lekuona Goya I, Zilberszac R, Gabriel H, Wisser W, Maurer G, Rosenhek R, Fabris E, Morosin M, Moretti M, Pinamonti B, Merlo M, Barbati G, Pappalardo A, Sinagra G. Moderated Posters session * New insights into risk stratification in valvular heart disease - Part A: 11/12/2013, 09:30-16:00 * Location: Moderated Poster area. Eur Heart J Cardiovasc Imaging 2013. [DOI: 10.1093/ehjci/jet208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Caiani E, Pellegrini A, Carminati M, Lang R, Auricchio A, Vaida P, Obase K, Sakakura T, Komeda M, Okura H, Yoshida K, Zeppellini R, Noni M, Rigo T, Erente G, Carasi M, Costa A, Ramondo B, Thorell L, Akesson-Lindow T, Shahgaldi K, Germanakis I, Fotaki A, Peppes S, Sifakis S, Parthenakis F, Makrigiannakis A, Richter U, Sveric K, Forkmann M, Wunderlich C, Strasser R, Djikic D, Potpara T, Polovina M, Marcetic Z, Peric V, Ostenfeld E, Werther-Evaldsson A, Engblom H, Ingvarsson A, Roijer A, Meurling C, Holm J, Radegran G, Carlsson M, Tabuchi H, Yamanaka T, Katahira Y, Tanaka M, Kurokawa T, Nakajima H, Ohtsuki S, Saijo Y, Yambe T, D'alto M, Romeo E, Argiento P, D'andrea A, Vanderpool R, Correra A, Sarubbi B, Calabro' R, Russo M, Naeije R, Saha SK, Warsame TA, Caelian AG, Malicse M, Kiotsekoglou A, Omran AS, Sharif D, Sharif-Rasslan A, Shahla C, Khalil A, Rosenschein U, Erturk M, Oner E, Kalkan A, Pusuroglu H, Ozyilmaz S, Akgul O, Aksu H, Akturk F, Celik O, Uslu N, Bandera F, Pellegrino M, Generati G, Donghi V, Alfonzetti E, Guazzi M, Rangel I, Goncalves A, Sousa C, Correia A, Martins E, Silva-Cardoso J, Macedo F, Maciel M, Lee S, Kim W, Yun H, Jung L, Kim E, Ko J, Enescu O, Florescu M, Rimbas R, Cinteza M, Vinereanu D, Kosmala W, Rojek A, Cielecka-Prynda M, Laczmanski L, Mysiak A, Przewlocka-Kosmala M, Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Gaudron P, Knop S, Ertl G, Bijnens B, Weidemann F, Saravi M, Tamadoni A, Jalalian R, Hojati M, Ramezani S, Yildiz A, Inci U, Bilik M, Yuksel M, Oyumlu M, Kayan F, Ozaydogdu N, Aydin M, Akil M, Tekbas E, Shang Q, Zhang Q, Fang F, Wang S, Li R, Lee AP, Yu C, Mornos C, Ionac A, Cozma D, Popescu I, Ionescu G, Dan R, Petrescu L, Sawant A, Srivatsa S, Adhikari P, Mills P, Srivatsa S, Boshchenko A, Vrublevsky A, Karpov R, Trifunovic D, Stankovic S, Vujisic-Tesic B, Petrovic M, Nedeljkovic I, Banovic M, Tesic M, Petrovic M, Dragovic M, Ostojic M, Zencirci E, Esen Zencirci A, Degirmencioglu A, Karakus G, Ekmekci A, Erdem A, Ozden K, Erer H, Akyol A, Eren M, Zamfir D, Tautu O, Onciul S, Marinescu C, Onut R, Comanescu I, Oprescu N, Iancovici S, Dorobantu M, Melao F, Pereira M, Ribeiro V, Oliveira S, Araujo C, Subirana I, Marrugat J, Dias P, Azevedo A, Grillo MT, Piamonti B, Abate E, Porto A, Dell'angela L, Gatti G, Poletti A, Pappalardo A, Sinagra G, Pinto-Teixeira P, Galrinho A, Branco L, Fiarresga A, Sousa L, Cacela D, Portugal G, Rio P, Abreu J, Ferreira R, Fadel B, Abdullah N, Al-Admawi M, Pergola V, Bech-Hanssen O, Di Salvo G, Tigen MK, Pala S, Karaahmet T, Dundar C, Bulut M, Izgi A, Esen AM, Kirma C, Boerlage-Van Dijk K, Yamawaki M, Wiegerinck E, Meregalli P, Bindraban N, Vis M, Koch K, Piek J, Bouma B, Baan J, Mizia M, Sikora-Puz A, Gieszczyk-Strozik K, Lasota B, Chmiel A, Chudek J, Jasinski M, Deja M, Mizia-Stec K, Silva Fazendas Adame PR, Caldeira D, Stuart B, Almeida S, Cruz I, Ferreira A, Lopes L, Joao I, Cotrim C, Pereira H, Unger P, Dedobbeleer C, Stoupel E, Preumont N, Argacha J, Berkenboom G, Van Camp G, Malev E, Reeva S, Vasina L, Pshepiy A, Korshunova A, Timofeev E, Zemtsovsky E, Jorgensen PG, Jensen J, Fritz-Hansen T, Biering-Sorensen T, Jons C, Olsen N, Henri C, Magne J, Dulgheru R, Laaraibi S, Voilliot D, Kou S, Pierard L, Lancellotti P, Tayyareci Y, Dworakowski R, Kogoj P, Reiken J, Kenny C, Maccarthy P, Wendler O, Monaghan M, Song J, Ha T, Jung Y, Seo M, Choi S, Kim Y, Sun B, Kim D, Kang D, Song J, Le Tourneau T, Topilsky Y, Inamo J, Mahoney D, Suri R, Schaff H, Enriquez-Sarano M, Bonaque Gonzalez J, Sanchez Espino A, Merchan Ortega G, Bolivar Herrera N, Ikuta I, Macancela Quinonez J, Munoz Troyano S, Ferrer Lopez R, Gomez Recio M, Dreyfus J, Cimadevilla C, Brochet E, Himbert D, Iung B, Vahanian A, Messika-Zeitoun D, Izumo M, Takeuchi M, Seo Y, Yamashita E, Suzuki K, Ishizu T, Sato K, Aonuma K, Otsuji Y, Akashi Y, Muraru D, Addetia K, Veronesi F, Corsi C, Mor-Avi V, Yamat M, Weinert L, Lang R, Badano L, Minamisawa M, Koyama J, Kozuka A, Motoki H, Izawa A, Tomita T, Miyashita Y, Ikeda U, Florescu C, Niemann M, Liu D, Hu K, Herrmann S, Gaudron P, Scholz F, Stoerk S, Ertl G, Weidemann F, Marchel M, Serafin A, Kochanowski J, Piatkowski R, Madej-Pilarczyk A, Filipiak K, Hausmanowa-Petrusewicz I, Opolski G, Meimoun P, M'barek D, Clerc J, Neikova A, Elmkies F, Tzvetkov B, Luycx-Bore A, Cardoso C, Zemir H, Mansencal N, Arslan M, El Mahmoud R, Pilliere R, Dubourg O, Ikonomidis I, Lambadiari V, Pavlidis G, Koukoulis C, Kousathana F, Varoudi M, Tritakis V, Triantafyllidi H, Dimitriadis G, Lekakis I, Kovacs A, Kosztin A, Solymossy K, Celeng C, Apor A, Faludi M, Berta K, Szeplaki G, Foldes G, Merkely B, Kimura K, Daimon M, Nakajima T, Motoyoshi Y, Komori T, Nakao T, Kawata T, Uno K, Takenaka K, Komuro I, Gabric ID, Vazdar L, Pintaric H, Planinc D, Vinter O, Trbusic M, Bulj N, Nobre Menezes M, Silva Marques J, Magalhaes R, Carvalho V, Costa P, Brito D, Almeida A, Nunes-Diogo A, Davidsen ES, Bergerot C, Ernande L, Barthelet M, Thivolet S, Decker-Bellaton A, Altman M, Thibault H, Moulin P, Derumeaux G, Huttin O, Voilliot D, Frikha Z, Aliot E, Venner C, Juilliere Y, Selton-Suty C, Yamada T, Ooshima M, Hayashi H, Okabe S, Johno H, Murata H, Charalampopoulos A, Tzoulaki I, Howard L, Davies R, Gin-Sing W, Grapsa J, Wilkins M, Gibbs J, Castillo J, Bandeira A, Albuquerque E, Silveira C, Pyankov V, Chuyasova Y, Lichodziejewska B, Goliszek S, Kurnicka K, Dzikowska Diduch O, Kostrubiec M, Krupa M, Grudzka K, Ciurzynski M, Palczewski P, Pruszczyk P, Arana X, Oria G, Onaindia J, Rodriguez I, Velasco S, Cacicedo A, Palomar S, Subinas A, Zumalde J, Laraudogoitia E, Saeed S, Kokorina M, Fromm A, Oeygarden H, Waje-Andreassen U, Gerdts E, Gomez E, Vallejo N, Pedro-Botet L, Mateu L, Nunyez R, Llobera L, Bayes A, Sabria M, Antonini-Canterin F, Mateescu A, La Carrubba S, Vriz O, Di Bello V, Carerj S, Zito C, Ginghina C, Popescu B, Nicolosi G, Mateescu A, La Carrubba S, Vriz O, Di Bello V, Carerj S, Zito C, Ginghina C, Popescu B, Nicolosi G, Antonini-Canterin F, Pudil R, Praus R, Vasatova M, Vojacek J, Palicka V, Hulek P, Pradel S, Mohty D, Damy T, Echahidi N, Lavergne D, Virot P, Aboyans V, Jaccard A, Mateescu A, La Carrubba S, Vriz O, Di Bello V, Carerj S, Zito C, Ginghina C, Popescu B, Nicolosi G, Antonini-Canterin F, Doulaptsis C, Symons R, Matos A, Florian A, Masci P, Dymarkowski S, Janssens S, Bogaert J, Lestuzzi C, Moreo A, Celik S, Lafaras C, Dequanter D, Tomkowski W, De Biasio M, Cervesato E, Massa L, Imazio M, Watanabe N, Kijima Y, Akagi T, Toh N, Oe H, Nakagawa K, Tanabe Y, Ikeda M, Okada K, Ito H, Milanesi O, Biffanti R, Varotto E, Cerutti A, Reffo E, Castaldi B, Maschietto N, Vida V, Padalino M, Stellin G, Bejiqi R, Retkoceri R, Bejiqi H, Retkoceri A, Surdulli S, Massoure P, Cautela J, Roche N, Chenilleau M, Gil J, Fourcade L, Akhundova A, Cincin A, Sunbul M, Sari I, Tigen M, Basaran Y, Suermeci G, Butz T, Schilling I, Sasko B, Liebeton J, Van Bracht M, Tzikas S, Prull M, Wennemann R, Trappe H, Attenhofer Jost CH, Pfyffer M, Scharf C, Seifert B, Faeh-Gunz A, Naegeli B, Candinas R, Medeiros-Domingo A, Wierzbowska-Drabik K, Roszczyk N, Sobczak M, Plewka M, Krecki R, Kasprzak J, Ikonomidis I, Varoudi M, Papadavid E, Theodoropoulos K, Papadakis I, Pavlidis G, Triantafyllidi H, Anastasiou - Nana M, Rigopoulos D, Lekakis J, Tereshina O, Surkova E, Vachev A, Merchan Ortega G, Bonaque Gonzalez J, Sanchez Espino A, Bolivar Herrera N, Bravo Bustos D, Ikuta I, Aguado Martin M, Navarro Garcia F, Ruiz Lopez F, Gomez Recio M, Merchan Ortega G, Bonaque Gonzalez J, Bravo Bustos D, Sanchez Espino A, Bolivar Herrera N, Bonaque Gonzalez J, Navarro Garcia F, Aguado Martin M, Ruiz Lopez M, Gomez Recio M, Eguchi H, Maruo T, Endo K, Nakamura K, Yokota K, Fuku Y, Yamamoto H, Komiya T, Kadota K, Mitsudo K, Nagy AI, Manouras A, Gunyeli E, Shahgaldi K, Winter R, Hoffmann R, Barletta G, Von Bardeleben S, Kasprzak J, Greis C, Vanoverschelde J, Becher H, Hu K, Liu D, Niemann M, Herrmann S, Cikes M, Gaudron P, Knop S, Ertl G, Bijnens B, Weidemann F, Di Salvo G, Al Bulbul Z, Issa Z, Khan A, Faiz A, Rahmatullah S, Fadel B, Siblini G, Al Fayyadh M, Menting ME, Van Den Bosch A, Mcghie J, Cuypers J, Witsenburg M, Van Dalen B, Geleijnse M, Roos-Hesselink J, Olsen F, Jorgensen P, Mogelvang R, Jensen J, Fritz-Hansen T, Bech J, Biering-Sorensen T, Agoston G, Pap R, Saghy L, Forster T, Varga A, Scandura S, Capodanno D, Dipasqua F, Mangiafico S, Caggegi AM, Grasso C, Pistritto AM, Imme' S, Ministeri M, Tamburino C, Cameli M, Lisi M, D'ascenzi F, Cameli P, Losito M, Sparla S, Lunghetti S, Favilli R, Fineschi M, Mondillo S, Ojaghihaghighi Z, Javani B, Haghjoo M, Moladoust H, Shahrzad S, Ghadrdoust B, Altman M, Aussoleil A, Bergerot C, Bonnefoy-Cudraz E, Derumeaux GA, Thibault H, Shkolnik E, Vasyuk Y, Nesvetov V, Shkolnik L, Varlan G, Gronkova N, Kinova E, Borizanova A, Goudev A, Saracoglu E, Ural D, Sahin T, Al N, Cakmak H, Akbulut T, Akay K, Ural E, Mushtaq S, Andreini D, Pontone G, Bertella E, Conte E, Baggiano A, Annoni A, Formenti A, Fiorentini C, Pepi M, Cosgrove C, Carr L, Chao C, Dahiya A, Prasad S, Younger J, Biering-Sorensen T, Christensen L, Krieger D, Mogelvang R, Jensen J, Hojberg S, Host N, Karlsen F, Christensen H, Medressova A, Abikeyeva L, Dzhetybayeva S, Andossova S, Kuatbayev Y, Bekbossynova M, Bekbossynov S, Pya Y, Farsalinos K, Tsiapras D, Kyrzopoulos S, Spyrou A, Stefopoulos C, Romagna G, Tsimopoulou K, Tsakalou M, Voudris V, Cacicedo A, Velasco Del Castillo S, Anton Ladislao A, Aguirre Larracoechea U, Onaindia Gandarias J, Romero Pereiro A, Arana Achaga X, Zugazabeitia Irazabal G, Laraudogoitia Zaldumbide E, Lekuona Goya I, Varela A, Kotsovilis S, Salagianni M, Andreakos V, Davos C, Merchan Ortega G, Bonaque Gonzalez J, Sanchez Espino A, Bolivar Herrera N, Macancela Quinones J, Ikuta I, Ferrer Lopez R, Munoz Troyano S, Bravo Bustos D, Gomez Recio M. Poster session Friday 13 December - PM: 13/12/2013, 14:00-18:00 * Location: Poster area. Eur Heart J Cardiovasc Imaging 2013. [DOI: 10.1093/ehjci/jet206] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Muraru D, Addetia K, Veronesi F, Corsi C, Mor-Avi V, Yamat M, Weinert L, Lang R, Badano L, Faita F, Di Lascio N, Bruno R, Bianchini E, Ghiadoni L, Sicari R, Gemignani V, Angelis A, Ageli K, Ioakimidis N, Chrysohoou C, Agelakas A, Felekos I, Vaina S, Aznaourides K, Vlachopoulos C, Stefanadis C, Nemes A, Szolnoky G, Gavaller H, Gonczy A, Kemeny L, Forster T, Ramalho A, Placido R, Marta L, Menezes M, Magalhaes A, Cortez Dias N, Martins S, Almeida A, Pinto F, Nunes Diogo A, Botezatu CD, Enache R, Popescu B, Nastase O, Coman M, Ghiorghiu I, Calin A, Rosca M, Beladan C, Ginghina C, Grapsa J, Cabrita I, Durighel G, O'regan D, Dawson D, Nihoyannopoulos P, Pellicori P, Kallvikbacka-Bennett A, Zhang J, Lukaschuk E, Joseph A, Bourantas C, Loh H, Bragadeesh T, Clark A, Cleland J, Kallvikbacka-Bennett A, Pellicori P, Lomax S, Putzu P, Diercx R, Parsons S, Dicken B, Zhang J, Clark A, Cleland J, Vered Z, Adirevitz L, Dragu R, Blatt A, Karev E, Malca Y, Roytvarf A, Marek D, Sovova E, Berkova M, Cihalik C, Taborsky M, Lindqvist P, Tossavainen E, Soderberg S, Gonzales M, Gustavsson S, Henein M, Sonne C, Bott-Fluegel L, Hauck S, Lesevic H, Hadamitzky M, Wolf P, Kolb C, Bandera F, Pellegrino M, Generati G, Donghi V, Alfonzetti E, Castelvecchio S, Menicanti L, Guazzi M, Buchyte S, Rinkuniene D, Jurkevicius R, Smarz K, Zaborska B, Jaxa-Chamiec T, Maciejewski P, Budaj A, Santoro A, Federico Alvino F, Giovanni Antonelli G, Roberta Molle R, Matteo Bertini M, Stefano Lunghetti S, Sergio Mondillo S, Henri C, Magne J, Dulgheru R, Laaraibi S, Voilliot D, Kou S, Pierard L, Lancellotti P, Szulik M, Stabryla-Deska J, Kalinowski M, Sliwinska A, Szymala M, Lenarczyk R, Kalarus Z, Kukulski T, Yiangou K, Azina C, Yiangou A, Ioannides M, Chimonides S, Baysal S, Pirat B, Okyay K, Bal U, Muderrisoglu H, Popovic D, Ostojic M, Petrovic M, Vujisic-Tesic B, Arandjelovic A, Petrovic I, Banovic M, Popovic B, Vukcevic V, Damjanovic S, Velasco Del Castillo S, Onaindia Gandarias J, Arana Achaga X, Laraudogoitia Zaldumbide E, Rodriguez Sanchez I, Cacicedo De Bobadilla A, Romero Pereiro A, Aguirre Larracoechea U, Salinas T, Subinas A, Elzbieciak M, Wita K, Grabka M, Chmurawa J, Doruchowska A, Turski M, Filipecki A, Wybraniec M, Mizia-Stec K, Varho V, Karjalainen P, Lehtinen T, Airaksinen J, Ylitalo A, Kiviniemi T, Gargiulo P, Galderisi M, D' Amore C, Lo Iudice F, Savarese G, Casaretti L, Pellegrino A, Fabiani I, La Mura L, Perrone Filardi P, Kim JY, Chung W, Yu J, Choi Y, Park C, Youn H, Lee M, Nagy A, Manouras A, Gunyeli E, Gustafsson U, Shahgaldi K, Winter R, Johnsson J, Zagatina A, Krylova L, Zhuravskaya N, Vareldzyan Y, Tyurina T, Clitsenko O, Khalifa EA, Ashour Z, Elnagar W, Jung I, Seo H, Lee S, Lim D, Mizariene V, Verseckaite R, Janenaite J, Jonkaitiene R, Jurkevicius R, Sanchez Espino A, Bonaque Gonzalez J, Merchan Ortega G, Bolivar Herrera N, Ikuta I, Macancela Quinones J, Gomez Recio M, Silva Fazendas Adame PR, Caldeira D, Stuart B, Almeida S, Cruz I, Ferreira A, Freire G, Lopes L, Cotrim C, Pereira H, Mediratta A, Addetia K, Moss J, Nayak H, Yamat M, Weinert L, Mor-Avi V, Lang R, Al Amri I, Debonnaire P, Van Der Kley F, Schalij M, Bax J, Ajmone Marsan N, Delgado V, Schmidt FP, Gniewosz T, Jabs A, Munzel T, Jansen T, Kaempfner D, Hink U, Von Bardeleben R, Jose J, George O, Joseph G, Jose J, Adawi S, Najjar R, Ahronson D, Shiran A, Van Riel A, Boerlage - Van Dijk K, De Bruin - Bon H, Araki M, Meregalli P, Koch K, Vis M, Mulder B, Baan J, Bouma B, Marciniak A, Elton D, Glover K, Campbell I, Sharma R, Batalha S, Lourenco C, Oliveira Da Silva C, Manouras A, Shahgaldi K, Caballero L, Garcia-Lara J, Gonzalez-Carrillo J, Oliva M, Saura D, Garcia-Navarro M, Espinosa M, Pinar E, Valdes M, De La Morena G, Barreiro Perez M, Lopez Perez M, Roy D, Brecker S, Sharma R, Venkateshvaran A, Dash PK, Sola S, Barooah B, Govind SC, Winter R, Shahgaldi K, Brodin LA, Manouras A, Saura Espin D, Caballero Jimenez L, Gonzalez Carrillo J, Oliva Sandoval M, Lopez Ruiz M, Garcia Navarro M, Espinosa Garcia M, Valdes Chavarri M, De La Morena Valenzuela G, Gatti G, Dell'angela L, Pinamonti B, Benussi B, Sinagra G, Pappalardo A, Hernandez V, Saavedra J, Gonzalez A, Iglesias P, Civantos S, Guijarro G, Monereo S, Ikeda M, Toh N, Oe H, Tanabe Y, Watanabe N, Ito H, Ciampi Q, Cortigiani L, Pratali L, Rigo F, Villari B, Picano E, Sicari R, Yoon J, Sohn J, Kim Y, Chang H, Hong G, Kim T, Ha J, Choi B, Rim S, Choi E, Tibazarwa K, Sliwa K, Wonkam A, Mayosi B, Oryshchyn N, Ivaniv Y, Pavlyk S, Lourenco MR, Azevedo O, Moutinho J, Nogueira I, Fernandes M, Pereira V, Quelhas I, Lourenco A, Sunbul M, Tigen K, Karaahmet T, Dundar C, Ozben B, Guler A, Cincin A, Bulut M, Sari I, Basaran Y, Baydar O, Kadriye Kilickesmez K, Ugur Coskun U, Polat Canbolat P, Veysel Oktay V, Umit Yasar Sinan U, Okay Abaci O, Cuneyt Kocas C, Sinan Uner S, Serdar Kucukoglu S, Zaroui A, Mourali M, Ben Said R, Asmi M, Aloui H, Kaabachi N, Mechmeche R, Saberniak J, Hasselberg N, Borgquist R, Platonov P, Holst A, Edvardsen T, Haugaa K, Lourenco MR, Azevedo O, Nogueira I, Moutinho J, Fernandes M, Pereira V, Quelhas I, Lourenco A, Eran A, Yueksel D, Er F, Gassanov N, Rosenkranz S, Baldus S, Guedelhoefer H, Faust M, Caglayan E, Matveeva N, Nartsissova G, Chernjavskij A, Ippolito R, De Palma D, Muscariello R, Santoro C, Raia R, Schiano-Lomoriello V, Gargiulo F, Galderisi M, Lipari P, Bonapace S, Zenari L, Valbusa F, Rossi A, Lanzoni L, Canali G, Molon G, Campopiano E, Barbieri E, Ikonomidis I, Varoudi M, Papadavid E, Theodoropoulos K, Papadakis I, Pavlidis G, Triantafyllidi H, Anastasiou - Nana M, Rigopoulos D, Lekakis J, Sunbul M, Tigen K, Ozen G, Durmus E, Kivrak T, Cincin A, Ozben B, Atas H, Direskeneli H, Basaran Y, Stevanovic A, Dekleva M, Trajic S, Paunovic N, Simic A, Khan S, Mushemi-Blake S, Jouhra F, Dennes W, Monaghan M, Melikian N, Shah A, Maceira Gonzalez AM, Lopez-Lereu M, Monmeneu J, Igual B, Estornell J, Boraita A, Kosmala W, Rojek A, Bialy D, Mysiak A, Przewlocka-Kosmala M, Popescu I, Mancas S, Mornos C, Serbescu I, Ionescu G, Ionac A, Gaudron P, Niemann M, Herrmann S, Hu K, Liu D, Wojciech K, Frantz S, Bijnens B, Ertl G, Weidemann F, Maceira Gonzalez AM, Cosin-Sales J, Ruvira J, Diago J, Aguilar J, Igual B, Lopez-Lereu M, Monmeneu J, Estornell J, Cruz C, Pinho T, Madureira A, Lebreiro A, Dias C, Ramos I, Silva Cardoso J, Julia Maciel M, De Meester P, Van De Bruaene A, Herijgers P, Voigt JU, Budts W, Franzoso F, Voser E, Wohlmut C, Kellenberger C, Valsangiacomo Buechel E, Carrero C, Benger J, Parcerisa M, Falconi M, Oberti P, Granja M, Cagide A, Del Pasqua A, Secinaro A, Antonelli G, Iacomino M, Toscano A, Chinali M, Esposito C, Carotti A, Pongiglione G, Rinelli G, Youssef Moustafa A, Al Murayeh M, Al Masswary A, Al Sheikh K, Moselhy M, Dardir M, Deising J, Butz T, Suermeci G, Liebeton J, Wennemann R, Tzikas S, Van Bracht M, Prull M, Trappe HJ, Martin Hidalgo M, Delgado Ortega M, Ruiz Ortiz M, Mesa Rubio D, Carrasco Avalos F, Seoane Garcia T, Pan Alvarez-Ossorio M, Lopez Aguilera J, Puentes Chiachio M, Suarez De Lezo Cruz Conde J, Petrovic MT, Giga V, Stepanovic J, Tesic M, Jovanovic I, Djordjevic-Dikic A, Generati G, Pellegrino M, Bandera F, Donghi V, Alfonzetti E, Guazzi M, Piatkowski R, Kochanowski J, Scislo P, Opolski G, Zagatina A, Zhuravskaya N, Krylova L, Vareldzhyan Y, Tyurina T, Clitsenko O, Bombardini T, Gherardi S, Leone O, Picano E, Michelotto E, Ciccarone A, Tarantino N, Ostuni V, Rubino M, Genco W, Santoro G, Carretta D, Romito R, Colonna P, Cameli M, Lunghetti S, Lisi M, Curci V, Cameli P, Focardi M, Favilli R, Galderisi M, Mondillo S, Hoffmann R, Barletta G, Von Bardeleben S, Kasprzak J, Greis C, Vanoverschelde J, Becher H, Machida T, Izumo M, Suzuki K, Kaimijima R, Mizukoshi K, Manabe-Uematsu M, Takai M, Harada T, Akashi Y, Martin Garcia A, Arribas-Jimenez A, Cruz-Gonzalez I, Nieto F, Iscar A, Merchan S, Martin-Luengo C, Brecht A, Theres L, Spethmann S, Dreger H, Baumann G, Knebel F, Jasaityte R, Heyde B, Rademakers F, Claus P, D'hooge J, Lervik Nilsen LC, Lund J, Brekke B, Stoylen A, Giraldeau G, Duchateau N, Gabrielli L, Penela D, Evertz R, Mont L, Brugada J, Berruezo A, Bijnens B, Sitges M, Kordybach M, Kowalski M, Hoffman P, Pilichowska E, Zaborska B, Baran J, Kulakowski P, Budaj A, Wahi S, Vollbon W, Leano R, Thomas A, Bricknell K, Holland D, Napier S, Stanton T, Teferici D, Qirko S, Petrela E, Dibra A, Bajraktari G, Bara P, Sanchis Ruiz L, Gabrielli L, Andrea R, Falces C, Duchateau N, Perez-Villa F, Bijnens B, Sitges M, Sulemane S, Panoulas V, Bratsas A, Tam F, Nihoyannopoulos P, Abduch M, Alencar A, Coracin F, Barban A, Saboya R, Dulley F, Mathias W, Vieira M, Buccheri S, Mangiafico S, Arcidiacono A, Bottari V, Leggio S, Tamburino C, Monte IP, Cruz C, Lebreiro A, Pinho T, Dias C, Silva Cardoso J, Julia Maciel M, Spitzer E, Beitzke D, Kaneider A, Pavo N, Gottsauner-Wolf M, Wolf F, Loewe C, Mushtaq S, Andreini D, Pontone G, Bertella E, Conte E, Baggiano A, Annoni A, Cortinovis S, Fiorentini C, Pepi M, Gustafsson M, Alehagen U, Dahlstrom U, Johansson P, Faden G, Faggiano P, Albertini L, Reverberi C, Gaibazzi N, Taylor RJ, Moody W, Umar F, Edwards N, Townend J, Steeds R, Leyva F, Mihaila S, Muraru D, Piasentini E, Peluso D, Casablanca S, Naso P, Puma L, Iliceto S, Vinereanu D, Badano L, Ciciarello FL, Agati L, Cimino S, De Luca L, Petronilli V, Fedele F, Tsverava M. Poster Session Saturday 14 December - AM: 14/12/2013, 08:30-12:30 * Location: Poster area. Eur Heart J Cardiovasc Imaging 2013. [DOI: 10.1093/ehjci/jet207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Abstract
Extensive evidence suggests that the immune system exerts powerful effects on bone cells, particularly in chronic disease pathologies such as rheumatoid arthritis (RA). The chronic inflammatory state in RA, particularly the excessive production of T cell-derived proinflammatory cytokines such as tumour necrosis factor (TNF)-α and interleukin (IL)-17, triggers bone erosions through the increased stimulation of osteoclast formation and activity. While evidence supports a role for IL-17 and TNF-α secreted by conventional CD4+ T cells in RA, recent evidence in animal models of RA have implicated γδ T cells as a major producer of pathogenic IL-17. However, the capacity of γδ T cells to influence osteoclast formation and activity in humans has not yet been investigated widely. To address this issue we investigated the effects of γδ T cells on osteoclast differentiation and resorptive activity. We have demonstrated that anti-CD3/CD28-stimulated γδ T cells or CD4+ T cells inhibit human osteoclast formation and resorptive activity in vitro. Furthermore, we assessed cytokine production by CD3/CD28-stimulated γδ T cells and observed a lack of IL-17 production, with activated γδ T cells producing abundant interferon (IFN)-γ. The neutralization of IFN-γ markedly restored the formation of osteoclasts from precursor cells and the resorptive activity of mature osteoclasts, suggesting that IFN-γ is the major factor responsible for the inhibitory role of activated γδ T cells on osteoclastogenesis and resorptive activity of mature osteoclasts. Our work therefore provides new insights on the interactions between γδ T cells and osteoclasts in humans.
Collapse
Affiliation(s)
- A Pappalardo
- Musculoskeletal Research Programme, Institute of Medical Sciences, Aberdeen, UK
| | | |
Collapse
|
46
|
Pedullà E, Plotino G, Grande NM, Scibilia M, Pappalardo A, Malagnino VA, Rapisarda E. Influence of rotational speed on the cyclic fatigue of Mtwo instruments. Int Endod J 2013; 47:514-9. [DOI: 10.1111/iej.12178] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2013] [Accepted: 07/20/2013] [Indexed: 02/01/2023]
Affiliation(s)
- E. Pedullà
- Department of Surgery; University of Catania; Catania Italy
| | - G. Plotino
- Department of Endodontics; ‘Sapienza’ University of Rome; Rome Italy
| | - N. M. Grande
- Department of Endodontics; ‘Sapienza’ University of Rome; Rome Italy
| | - M. Scibilia
- Department of Surgery; University of Catania; Catania Italy
| | - A. Pappalardo
- Department of Surgery; University of Catania; Catania Italy
| | - V. A. Malagnino
- Department of Oral Medical Sciences and Biotechnology; University of Chieti; Chieti Italy
| | - E. Rapisarda
- Department of Surgery; University of Catania; Catania Italy
| |
Collapse
|
47
|
Patti F, Nicoletti A, Pappalardo A, Castiglione A, Lo Fermo S, Messina S, D'Amico E, Cimino V, Zappia M. Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis. Acta Neurol Scand 2012; 125:91-5. [PMID: 21649611 DOI: 10.1111/j.1600-0404.2011.01532.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND The relationship between multiple sclerosis (MS) and headache (HA) is not well known. It was reported that interferon-beta (IFNβ) could induce or worsen HA. OBJECTIVE To evaluate the impact of IFNβ treatment on HA and the relationship between HA and the various commercial preparations of IFNβ in mildly disabled patients with MS. METHODS A specific questionnaire was administered to 357 relapsing-remitting MS patients. Characteristics of HAs were considered, including the temporal relationships with IFNβ administration. RESULTS One hundred and seventeen patients were treated with weekly intramuscular injections of interferon IFNβ-1a (Avonex(®)), 84 with subcutaneous injections of IFNβ-1b (Betaferon(®)) every other day, 48 and 108 with three times weekly subcutaneous injections of IFNβ-1a (Rebif(®)) 22 mcg or IFNβ-1a (Rebif(®)) 44 mcg, respectively. Three hundred and fourteen patients were affected by HA, and among them, 219 patients suffered of pre-existing HA. In this latter group, 121 subjects (55%) noted a worsening of their HA after starting IFNβ therapy; this was more frequently reported by patients treated with Avonex(®) and Rebif(®) 44. Ninety-five patients experienced new HA. CONCLUSION IFNβ treatment could worsen HA in patients with pre-existing HA or cause the appearance of new HA. Among different IFNβ preparations, Rebif(®) 44 and Avonex(®) seemed to be more cephalalgic than the other drugs.
Collapse
Affiliation(s)
- F Patti
- Department of Neurosciences, University of Catania, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Finocchiaro P, Barbagallo M, Cosentino L, Greco G, Guardo G, Pappalardo A, Scirè C, Scirè S. Silicon photomultipliers for radioactive waste online monitoring. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment 2011; 652:143-145. [DOI: 10.1016/j.nima.2010.07.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
49
|
Patti F, Amato MP, Trojano M, Solaro C, Pappalardo A, Zipoli V, Portaccio E, Paolicelli D, Paolillo A, Mennini FS, Marcellusi A, Ricci C, Battaglia MA. Multiple sclerosis in Italy: cost-of-illness study. Neurol Sci 2011; 32:787-94. [PMID: 21409509 DOI: 10.1007/s10072-011-0499-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2010] [Accepted: 02/16/2011] [Indexed: 12/01/2022]
Abstract
This study estimates the direct costs of multiple sclerosis (MS) in Italy from the perspective of the National Health System. Patients diagnosed with MS for ≥1 year prior to study entry were included in the analysis; neurological disability was assessed using the Expanded Disability Status Scale (EDSS). Cost variables were analyzed according to: MS phenotype, disease course over the previous year and EDSS rating. A total of 510 patients were included in the analysis. Overall costs were significantly higher for relapsing-remitting MS and secondary progressive MS than for primary progressive MS (P < 0.05). Costs were higher for EDSS scores 0.0-3.5 and 4.0-6.0 than for scores > 6.0 (P < 0.05). The extrapolated data gave an estimated annual direct cost of MS per patient of <euro>18,030. In conclusion, relapsing-remitting MS or secondary progressive MS phenotypes and lower estimated EDSS scores appear to be associated with higher costs.
Collapse
Affiliation(s)
- F Patti
- Multiple Sclerosis Centre Sicilia Region, First Neurology Clinic, University Hospital Catania, Catania, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Marti Almor J, Bazan V, Matiello M, Cian D, Oliva X, Altaba C, Guijo MA, Bruguera J, Fiala M, Sknouril M, Dorda M, Chovancik J, Nevralova R, Jiravsky O, Jiravska-Godula B, Branny M, Elvan A, Beukema WP, Smit JJJ, Delnoy PPHM, Ramdat Misier AR, Tuan J, Chung I, Jeilan M, Kundu S, Osman F, Stafford P, Ng GA, Vergara P, Mazzone P, Paglino G, Saviano M, Crisa S, Maida G, Vicedomini G, Pappone C, Miyazaki S, Wright M, Hocini M, Jais P, Haissaguerre M, Yoshitani K, Kaitani K, Hanazawa K, Nakagawa Y, Yokokawa M, Tada H, Naito S, Oshima S, Taniguchi K, Romanov A, Pokushalov E, Shugaev P, Artemenko S, Turov A, Gindele FM, Wiedemann M, Ewertsen C, Heiderfazel S, Andresen D, Kaitani K, Hanazawa K, Yoshitani K, Miyake M, Motooka M, Izumi T, Izumi C, Nakagawa Y, Sunthorn H, Burri HB, Gentil PG, Shah DS, Sugiura S, Fujii E, Senga M, Yamazato S, Nakamura M, Ito M, Den Uijl DW, Delgado V, Tops LF, Trines SAIP, Zeppenfeld K, Van Der Wall EE, Schalij MJ, Bax JJ, Pappalardo A, Forleo GB, Avella A, Bencardino G, De Girolamo PG, Dello Russo A, Laurenzi F, Tondo C, Mueller H, Burri H, Gentil-Baron P, Lerch R, Shah D, Pokushalov E, Romanov A, Turov A, Shugaev P, Artemenko S, Shirokova N, Pedrote Martinez AA, Arana E, Garcia-Riesco L, Urbano-Moral JA, Frutos-Lopez M, Sanchez-Brotons JA, Torres-Llergo J, Martinez-Martinez A, Matsuda H, Harada T, Nakano E, Takai M, Fujita S, Sasaki T, Mizuno K, Miyake F, Doshi A, Hummel J, Daoud E, Augostini R, Weiss R, Hart D, Houmsse M, Kalbfleisch S, Fiala M, Chovancik J, Gorzolka J, Bulkova V, Wojnarova D, Neuwirth R, Januska J, Branny M, Cerrato E, Amellone C, Tizzani E, Antolini M, Massa R, Golzio PG, Comoglio C, Rinaldi M, El-Domiaty HA, Kamal HM, Moubarak AM, Mansy MM, El-Kerdawy H, Ahmed S, Klinkenberg TJ, Ten Hagen A, Wiesfeld ACP, Tan ES, Van Gelder IC. Poster Session 1: Ablation of atrial fibrillation. Europace 2009. [DOI: 10.1093/europace/euq213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|